-Global Agreement Positions Sportradar as Core Data and Solutions Provider Across Premier Sports Leagues-

- Opportunity to participate across Kalshi ecosystem including market makers and brokers--

ST. GALLEN, Switzerland and NEW YORK, June 08, 2026 (GLOBE NEWSWIRE) -- Sportradar Group AG (NASDAQ: SRAD) today announced a landmark multi-year global agreement with Kalshi, the world's largest prediction market. This strategic agreement positions Sportradar as an official data and solutions provider for Kalshi, delivering a broad portfolio of premium sports content and services across major sports properties including Major League Baseball (MLB), the National Hockey League (NHL), Major League Soccer (MLS), and Ultimate Fighting Championship (UFC), among others.

As prediction markets continue to emerge as a fast growing and regulated segment of the sports ecosystem, Sportradar is positioned to play a foundational role in enabling their growth and facilitating a framework for integrity. This agreement also establishes the ability for Sportradar to enter into agreements directly with Kalshi's key partners, including brokers and market makers, with real time official data and scalable solutions across the value chain.

Sportradar will provide Kalshi with a range of solutions from Sportradar Prediction Services, including:

Official Sports Data and Live Odds: Fast, reliable, accurate official data and live odds to power pre-game and in-play markets, enhancing market efficiency while ensuring timely settlements

Fan Engagement Solutions: Dynamic, real-time content, including scores, schedules, and data visualizations, designed to drive deeper engagement

Customer Acquisition Solutions: Leading marketing services to help acquire high value sports fans

Industry-Leading Integrity Services: Robust integrity framework including Sportradar UFDS AI, which detects suspicious behavior, and Sportradar Integrity Exchange (SIE), which enables participants to share integrity threats through a secure network

The partnership underscores Sportradar's leading position as it extends its core data and premium solutions capabilities into adjacent, high-growth markets. By leveraging its global distribution model and deep relationships, Sportradar continues to broaden its commercial reach while reinforcing its position as critical infrastructure for the evolving sports industry.

Sportradar will provide products and services to Kalshi and other licensed prediction market entities that operate in compliance with applicable regulations and legal requirements.

Carsten Koerl, Chief Executive Officer of Sportradar, said: "Prediction markets represent a compelling growth engine for the global sports ecosystem and Sportradar is uniquely positioned to shape and power this emerging sector. Our partnership with Kalshi extends the reach of our premium sports data and services into a rapidly evolving landscape, fostering collaboration with market makers and the broader marketplace. This partnership with Kalshi marks a critical first step. We look forward to working with key prediction market participants as the landscape matures, establishing the trusted, compliant framework for sports innovation just as we have successfully delivered in online sports betting."

Tarek Mansour, co-founder and CEO of Kalshi, said: "The breadth and depth of this partnership is what makes it a big deal. We're using official league data to ensure quicker trade settlements, creating an overall better customer experience. We're also collaborating on an integrity monitoring program to further protect our users."

Sportradar Group AG

About Sportradar

Sportradar Group AG (NASDAQ: SRAD), founded in 2001, is a leading global sports technology company creating immersive experiences for sports fans and bettors. Positioned at the intersection of the sports media and betting/gaming industries, Sportradar provides betting and iGaming operators, media and technology companies, prediction market partners and sports federations with a best-in-class range of solutions to help grow their businesses. Trusted by the world's leading global sports organizations including the ATP, NBA and WNBA, NHL, MLB, MLS, PGA TOUR, UEFA, FIFA, CONMEBOL, AFC, and the Bundesliga, and global clients including Flutter, DraftKings, Google, Microsoft and Kalshi, Sportradar covers more than a million events annually across all major sports. Sportradar is not just redefining the sports fan experience, it also safeguards sports through its Integrity Services division and advocacy for an integrity-driven environment for all involved. For more information about Sportradar, please visit www.sportradar.com

About Kalshi

Founded in 2018, Kalshi is the world's largest prediction market. Prediction markets provide accurate, real-time information on the likelihood of events, making humanity more informed about the future. Kalshi is credited with legalizing and establishing prediction markets as a financial asset class. It's the leading safe and regulated platform trusted by millions of people in America. To learn more about Kalshi, visit www.kalshi.com.

CONTACT:

Media:

Sandra Lee

Sandra.lee@sportradar.com

Investor Relations:

Jim Bombassei

j.bombassei@sportradar.com

Elisabeth Diana

ediana@kalshi.com

Copyright 2026 GlobeNewswire, Inc.

The second edition of the popular topiary showcase introduces an interactive area starring Disney's Frozen, and more beloved Disney and Pixar character dioramas including Toy Story 5 and Disney Princess

SINGAPORE - Media OutReach Newswire - 8 June 2026 - Disney magic blooms anew at Singapore's premier horticultural destination Gardens by the Bay as the second edition of Disney Garden of Wonder, opens today. Featuring 23 vibrant topiaries inspired by beloved Disney and Pixar characters, the enchanting showcase transforms Floral Fantasy into a world of floral artistry and imagination through 14 March 2027.

Organised in collaboration with Disney and supported by the Singapore Tourism Board, Disney Garden of Wonder is inspired by Disney and Pixar stories that have charmed generations of fans around the world, inviting people of all ages to re-discover their favourite stories of courage, kindness, friendship and love through the beauty of plants. Following the success of its debut at Gardens by the Bay in 2024, the enthralling floral showcase returns in an even more special second edition.

Visitors can look forward to five themed areas:

Frozen, in which topiary versions of Anna, Elsa and Olaf preside over an enchanting snowy landscape, brought to life through themed lighting that imagines a frost-kissed world of wonder. Inspired by Elsa's Ice Palace, visitors can step on a floor where magical snowflakes dance and respond to movement.

Disney princesses, where Rapunzel appears alongside her best friend Pascal the chameleon; Belle is with the Beast and their enchanted companions; and Jasmine is accompanied by her loyal tiger Rajah.

Hundred Acre Wood, where Winnie the Pooh, Eeyore, Piglet and Tigger gather in a cheerful party scene. Tigger bounces up and down while Piglet twirls, and visitors can picture themselves joining everyone at the table!

Toy Story 5, where Woody, Jessie and Buzz Lightyear appear as topiaries in a playful setting inspired by Bonnie's Room, alongside displays of new characters Lilypad and Smarty Pants.

Go Local, a Singaporean-themed zone where Disney characters are reimagined in familiar local settings. Chip 'n Dale perch atop a giant ice cream sandwich; Minnie Mouse and Daisy Duck share the spicy rice noodle dish laksa; and Mickey Mouse makes the traditional beverage teh tarik with Donald Duck.

Outside Floral Fantasy, a 4m-tall Sorcerer's Apprentice Mickey marks the entrance and welcomes visitors to Gardens by the Bay.

The hand-assembled topiaries are crafted from more than 40 species of preserved and dried floral materials, which took more than 16,000 man hours.

Each material was selected for its colour, texture and form, helping to reflect each character's features. Plenty of flowers are used for the Disney princesses for example, while Rapunzel's hair is crafted from Stipa, a perennial grass that has fluffy or oat-like flowerheads.

The surrounding landscapes also use plant palettes that reflect the mood of each zone ? sunflowers and marigolds reflect the honey-toned meadow setting of Winnie the Pooh, while lilies and roses bring out the romantic and jewel-toned settings of Disney Princess stories. Hydrangeas and dusty miller evoke the icy blues, whites and silvers of Frozen.

Throughout the duration of Garden of Wonder, visitors can enjoy select weekend Meet and Greet sessions with Mickey Mouse and Minnie Mouse in outfits inspired by Singapore's national flower, the Vanda Miss Joaquim. Donald Duck and Daisy Duck will also join the experience on select weekends, dressed for a sunny getaway on our tropical island. Meet and Greet dates are available at www.gardensbythebay.com.sg/disneygardenofwonder.

Visitors can round off their experience with shopping at the gift shop, which carries items launching exclusively at Disney Garden of Wonder.

Disney Garden of Wonder

Date: 8 June 2026 to 14 March 2027

Time: 10am to 9pm

Venue: Floral Fantasy at Gardens by the Bay

Details: Tickets are priced at SG$24 for adults and SG$16 for children

Getting here: Take the MRT to Bayfront station. Alternatively, drop off at the Bayfront Plaza carpark via taxi or ride-hailing service. More information available here.

Visit www.gardensbythebay.com.sg/disneygardenofwonder for more details.

Gardens by the Bay

An integral part of Singapore's "City in Nature" vision, Gardens by the Bay is a national garden and premier horticultural attraction that showcases the best of garden and floral artistry for all to enjoy. Spanning 101 hectares in the heart of Singapore's downtown Marina Bay, it comprises three waterfront gardens - Bay South, Bay East, and Bay Central. Bay South, the largest at 54 hectares, officially opened on 29 June 2012.

Guided by the vision to be a world of gardens for all to own, enjoy and cherish, the Gardens' extensive plant collection, ever-changing floral displays, and myriad of engaging programmes have captured the imagination of many, while its Gift of Gardens community initiative, with Mr Tharman Shanmugaratnam, President of the Republic of Singapore as Patron, reaches out to people from all walks of life.

Since opening, Gardens by the Bay has welcomed more than 115 million visitors and garnered numerous international accolades including the third Top Attraction in the World in Tripadvisor Travelers' Choice Awards Best of the Best 2026, Outstanding Achievement in Sustainability at the Singapore Tourism Awards 2024, Best Theme Attraction at TTG Travel Awards 2022 and 2023, and Best Attraction Experience at the Singapore Tourism Awards 2019. The Gardens continues to refresh and refine its offerings, to be a place that everyone can enjoy - a garden where wonder blooms.

For more information, visit www.gardensbythebay.com.sg.

The issuer is solely responsible for the content of this announcement.

Hashtags: #DisneyGardenofWonder #FloralFantasy #GardensbytheBay

New analysis from the IMPACT-TD Registry demonstrates that treatment with AUSTEDO and AUSTEDO XR led to reductions in Abnormal Involuntary Movement Scale (AIMS) scores in all participants, which were associated with improved activities of daily living.

Further data from the 3-year RIM-TD study reinforces the importance of sustained treatment, showing >50% of patients achieve a clinically meaningful response to AUSTEDO by week 15, with additional patients achieving response with continued treatment.

The comprehensive data package presented at Psych Congress Elevate advances clinical understanding of TD from diagnosis to long-term management, underscoring Teva's commitment to improving outcomes for the full spectrum of individuals living with TD.

PARSIPPANY, N.J. and TEL AVIV, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data that highlight the comprehensive tardive dyskinesia (TD) symptom improvement from treatment with AUSTEDO and AUSTEDO XR. The new findings, drawn from three separate studies, were presented at Psych Congress Elevate, held June 3 - 6, 2026, in Las Vegas, NV.

"The data presented at Psych Congress Elevate represent Teva's pursuit to better understanding the full human experience of tardive dyskinesia," said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. "We are dedicated to not only advancing science but also striving to close critical gaps in diagnosis and clinical management of tardive dyskinesia. By generating robust evidence for a broader range of patients, including those with mild TD, and providing insights that guide optimal long-term treatment strategies, we are working to deliver innovations that make a meaningful difference in the day-to-day lives of those living with this condition."

The new findings from Teva's latest research revealed:

Benefit in Mild TD (IMPACT-TD): New real-world insights from the IMPACT-TD Registry, the largest real-world study of TD,1 evaluated patients with mild symptoms who were starting AUSTEDO or AUSTEDO XR treatment. At three months, all participants showed reductions in their Abnormal Involuntary Movement Scale (AIMS) score while maintaining their psychiatric stability; and participants with a clinically meaningful baseline burden in areas such as activities of daily living, psychosocial functioning, speech and communication reported improvement in these domains due to the reduction of TD movements.

Value of Sustained Treatment (RIM-TD): An analysis from the 3-year RIM-TD open-label study found that an increasing percentage of patients responded to treatment over the course of the study. While >50% showed AIMS improvement within 15 weeks, an additional 23% saw improvement after week 15. This underscores the possibility of increasing improvement when patients stay on treatment.

Closing the Diagnosis Gap: A study focused on caregiver education found that providing TD-specific educational content developed in collaboration with patient advocacy groups via online platforms prompted crucial conversations with healthcare professionals. Within six months, 53% of care recipients at risk of TD discussed TD with a provider, and 34% received a TD diagnosis, highlighting an effective strategy to improve disease recognition.

"These findings are significant because they add to the real-world evidence supporting treatment benefit for patients with mild tardive dyskinesia," said Richard Jackson, MD, Assistant Clinical Adjunct Professor at the University of Michigan School of Medicine's Department of Psychiatry and IMPACT-TD principal investigator. "In clinical practice, we know that even so-called 'mild' involuntary movements can have a profound, multidimensional impact on a person's quality of life. These data give clinicians greater confidence to identify and treat TD early, offering the potential to improve outcomes for patients who might have previously been overlooked."

Teva remains deeply committed to advancing the science of tardive dyskinesia and supporting the full needs of the TD community.

About Tardive Dyskinesia (TD)

Tardive dyskinesia (TD) is a highly debilitating, chronic movement disorder that affects one in four people who take certain mental health treatments and is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts, which may be disruptive and negatively impact individuals.2,3,4

About AUSTEDO XR Extended-Release Tablets and AUSTEDO Tablets

AUSTEDO XR and AUSTEDO are the first vesicular monoamine transporter 2 (VMAT2) inhibitors approved by the U.S. Food and Drug Administration in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington's disease. Safety and effectiveness in pediatric patients have not been established. AUSTEDO XR is the once-daily formulation of AUSTEDO.

INDICATIONS AND USAGE

AUSTEDO XR (deutetrabenazine) extended-release tablets and AUSTEDO (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington's disease and for the treatment of tardive dyskinesia.

IMPORTANT SAFETY INFORMATION 

Depression and Suicidality in Patients with Huntington's Disease: AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidality and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation. AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression. 

Contraindications: AUSTEDO XR and AUSTEDO are contraindicated in patients with Huntington's disease who are suicidal, or have untreated or inadequately treated depression. AUSTEDO XR and AUSTEDO are also contraindicated in: patients with hepatic impairment; patients taking reserpine or within 20 days of discontinuing reserpine; patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing MAOI therapy; and patients taking tetrabenazine or valbenazine.   

Clinical Worsening and Adverse Events in Patients with Huntington's Disease: AUSTEDO XR and AUSTEDO may cause a worsening in mood, cognition, rigidity, and functional capacity. Prescribers should periodically re-evaluate the need for AUSTEDO XR or AUSTEDO in their patients by assessing the effect on chorea and possible adverse effects. 

QTc Prolongation: AUSTEDO XR and AUSTEDO may prolong the QT interval, but the degree of QT prolongation is not clinically significant when AUSTEDO XR or AUSTEDO is administered within the recommended dosage range. AUSTEDO XR and AUSTEDO should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.  

Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex reported in association with drugs that reduce dopaminergic transmission, has been observed in patients receiving tetrabenazine. The risk may be increased by concomitant use of dopamine antagonists or antipsychotics. The management of NMS should include immediate discontinuation of AUSTEDO XR and AUSTEDO; intensive symptomatic treatment and medical monitoring; and treatment of any concomitant serious medical problems.   

Akathisia, Agitation, and Restlessness: AUSTEDO XR and AUSTEDO may increase the risk of akathisia, agitation, and restlessness. The risk of akathisia may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops akathisia, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy. 

Parkinsonism: AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntington's disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. The risk of parkinsonism may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops parkinsonism, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy. 

Sedation and Somnolence: Sedation is a common dose-limiting adverse reaction of AUSTEDO XR and AUSTEDO. Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, until they are on a maintenance dose of AUSTEDO XR or AUSTEDO and know how the drug affects them. Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence. 

Hyperprolactinemia: Tetrabenazine elevates serum prolactin concentrations in humans. If there is a clinical suspicion of symptomatic hyperprolactinemia, appropriate laboratory testing should be done and consideration should be given to discontinuation of AUSTEDO XR and AUSTEDO.   

Binding to Melanin-Containing Tissues: Deutetrabenazine or its metabolites bind to melanin-containing tissues and could accumulate in these tissues over time. Prescribers should be aware of the possibility of long-term ophthalmologic effects. 

Common Adverse Reactions: The most common adverse reactions for AUSTEDO (>8% and greater than placebo) in a controlled clinical study in patients with Huntington's disease were somnolence, diarrhea, dry mouth, and fatigue. The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia.  Adverse reactions with AUSTEDO XR extended-release tablets are expected to be similar to AUSTEDO tablets. 

Please see accompanying full Prescribing Information, including Boxed Warning. 

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Teva Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize AUSTEDO and AUSTEDO XR for the treatment of tardive dyskinesia; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors" and "Forward-Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

References:

Data on file. Parsippany, NJ: Teva Neuroscience, Inc.

Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. J Clin Psychiatry. 2017;78(3):e264-e278. doi: 10.4088/JCP.16r10832.

Waln O, Jankovic J. An Update on Tardive Dyskinesia: From Phenomenology to Treatment. Tremor Other Hyperkinet Mov. 2013;3:1-11.

Tardive dyskinesia. National Alliance on Mental Illness website. https://www.nami.org/Learn-More/Treatment/Mental-Health-Medications/Tardive-Dyskinesia. Accessed May 4, 2026.

Teva Media Inquiries TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor Relations Inquiries TevaIR@Tevapharm.com

Copyright 2026 GlobeNewswire, Inc.

ZURICH, June 08, 2026 (GLOBE NEWSWIRE) --

The Geneva Association announces today that Lard Friese, CEO and Chairman of the Executive Committee of Aegon, was appointed Chair of the organisation at its spring 2026 board meeting on 3 June. Lard Friese has been Vice Chair of the Geneva Association since November 2024 and succeeds Lee Yuan Siong, Group Chief Executive & President of AIA, who will remain on the board following completion of his term as Chair.

Two Geneva Association members were also elected to the board of directors at the 2026 General Assembly on 4 June:

Christoph Jurecka, Chair of the Board of Management, Munich Re

Tim Sweeney, Chairman, President and CEO, Liberty Mutual Insurance

Lard Friese, Chair of the Geneva Association and CEO of Aegon, said: "I am grateful to Lee Yuan Siong for his outstanding leadership over the past two years. It is a privilege to succeed him as Chair of the Geneva Association, an organisation that plays such an important role in shaping the understanding of global risk and resilience.

"At a time of heightened uncertainty, fragmentation, and interconnected risks, the industry's collective insight and evidence-based research are more important than ever. I am also delighted to welcome Christoph Jurecka and Tim Sweeney to the board of directors, and I look forward to working with them and all Geneva Association Board members, in addition to Jad Ariss and the Geneva Association team, to advance our mission."

Jad Ariss, Managing Director of the Geneva Association, said: "I would like to thank Lee Yuan Siong for his vision and dedication. It has been an honour to work alongside him in advancing our belief in 'Insurance for a Better World'. Under his leadership, we have significantly grown our membership in Asia and heightened the Association's profile across the region, enhancing our global reach and long-term impact.

"I am delighted that Lard Friese has been appointed Chair and I look forward to working with him. I also warmly welcome new board members Christoph Jurecka and Tim Sweeney. Together with the wider board, we will ensure that the Geneva Association continues to provide the research, dialogue and leadership needed to help the industry navigate an increasingly complex risk landscape."

The Geneva Association's spring 2026 board meeting took place ahead of the organisation's annual, two-day General Assembly, which gathered 61 global insurance CEOs in Madrid, Spain under the theme, 'A World Under Strain: Resilience Amid Fragmentation.'         

The Geneva Association is the only global association of insurance companies; its members are insurance and reinsurance CEOs. Based on rigorous research conducted in collaboration with its members, academic institutions and multilateral organisations, The Geneva Association investigates key risk areas that are likely to impact the insurance industry, develops recommendations and provides a platform for stakeholders to discuss them. In total, the companies of Geneva Association members are headquartered in 26 countries around the world; manage USD 21 trillion in assets; employ more than 2.5 million people; and protect 2.6 billion people.

Download the press release: https://www.genevaassociation.org/press-releases/lard-friese-ceo-aegon-becomes-chair-geneva-association

Contact:

Pamela Corn

Director of Communications

+41 44 200 49 96

pamela_corn@genevaassociation.org

Copyright 2026 GlobeNewswire, Inc.

ADI Predictstreet, FIFA's Official Prediction Market Partner of the FIFA World Cup 2026, will enable secure, transparent, and scalable participation ahead of the world's largest sporting event

ADI Predictstreet is built on ADI Chain's institutional-grade digital infrastructure, ready to support consumer-facing applications at global scale

GIBRALTAR, June 08, 2026 (GLOBE NEWSWIRE) -- ADI Predictstreet, the new global prediction market platform, today announced its official launch, marking a major milestone in the evolution of how soccer fans engage with the sport. 

Launching ahead of the record-breaking FIFA World Cup 2026 - set to be the largest edition in the tournament's history - ADI Predictstreet will leverage historical FIFA data and bring real-time predictive engagement to football fans around the world. As FIFA's Official Prediction Market Partner of the FIFA World Cup 2026, the platform enables users to actively participate in matches through real-time predictions, sentiment tracking and dynamic, interactive experiences tied to live moments on the pitch.

ADI Predictstreet combines seamless live content and rapid market resolution into a single prediction market experience. Users can fund their accounts using both digital assets and traditional fiat payment methods, while integrated live streaming of every FIFA World Cup 2026 match allows fans in designated jurisdictions to watch and predict from the same platform. Powered by a near real-time resolution engine, eligible markets are confirmed quickly, enabling faster balance updates and a more responsive user experience. 

ADI Predictstreet is now operating within regulated markets. Initially launched in Gibraltar, ADI Predictstreet - through a recently announced partnership with Fanatics Markets - is now also available in 23 states across the U.S. via the co-branded World Cup Hub. The World Cup Hub offers fans expanded global football prediction markets alongside tournament news, official player data and in-app content designed to enhance the FIFA World Cup 2026 trading experience. 

Consumers in other global jurisdictions are expected to have access to ADI Predictstreet through a growing network of compliant strategic partners, creating a scalable pathway to regulated market access globally. The ADI Predictstreet platform is available to fans online via mobile and desktop at adipredictstreet.com, offering a seamless and accessible way to engage with the game.  

ADI Predictstreet will continue to pursue a disciplined, jurisdiction-by-jurisdiction expansion strategy to ensure the platform operates in full alignment with applicable legal and regulatory requirements. As the regulatory environment for prediction markets continues to evolve, the company remains focused on maintaining the highest standards of transparency, compliance, and user protection.

"ADI Predictstreet was created to redefine how fans engage with live events," said Dimitrios Psarrakis, CEO of ADI Predictstreet. "As we go live ahead of the FIFA World Cup 2026, we are proud to deliver a secure, regulated, and globally scalable platform that combines technology, prediction markets, and real-time participation at an unprecedented level. Billions of fans worldwide will engage with this summer's historic tournament, alongside millions in person across North America. We look forward to introducing them all to a new and exciting way of engaging with the FIFA World Cup 2026."

ADI Chain's Infrastructure 

ADI Predictstreet is the first consumer-facing application deployed on ADI Chain's institutional-grade blockchain infrastructure. Its official launch is an important milestone in ADI Predictstreet's broader ambition to become the primary destination for understanding what the world believes will happen next, with markets eventually spanning global events across finance, technology and culture. 

Built on ADI Chain's compliance-ready infrastructure, ADI Predictstreet delivers real-time market signals, performance tracking, and embedded safeguards to ensure fairness, integrity, and participant protection. 

Platform Security and Integrity

In furtherance of its commitment to transparency, market integrity, and responsible market operations, ADI Predictstreet maintains a comprehensive, risk-based surveillance and compliance framework designed to promote fair and orderly participation and identify potentially suspicious, manipulative, fraudulent, or otherwise prohibited activity.

The framework incorporates multiple layers of preventive and detective controls, including customer identity verification and AML screening through Sumsub, blockchain analytics and wallet monitoring through Global Ledger, and transaction surveillance capabilities supported by Modulus. ADI Predictstreet also utilizes official and independent sports data sources, including Sportradar, Stats Perform, and LSports Data, to support accurate market settlement, operational resilience, and data integrity.

High-Impact Partnership

Today's launch follows the recent partnership announcement between ADI Predictstreet and DAZN, the world's leading sports entertainment platform, which will see prediction markets embedded into live sports streaming environments globally. 

As the countdown to kick-off for the FIFA World Cup 2026 begins, ADI Predictstreet stands ready, live, regulated, and built for the world's biggest moments.

About ADI Predictstreet:

ADI Predictstreet is a Gibraltar-licensed and regulated prediction market platform and the Official Prediction Market Partner of the FIFA World Cup 2026, enabling users to forecast outcomes first in football, and eventually through global news, technology, and culture. By harnessing collective intelligence from a global community, the platform transforms sentiment into measurable probabilities, creating a new model for digital participation and decision-making. Built on ADI Chain's compliance-ready infrastructure, the first institutional Layer 2 blockchain for stablecoins and real-world assets in the MENA region, ADI Predictstreet is designed to scale into thousands of prediction markets worldwide in the future where individuals and communities can engage with and anticipate what happens next.

For more information visit: adipredictstreet.com 

Email: media@adipredictstreet.com 

Copyright 2026 GlobeNewswire, Inc.

AI-powered PlayOS, revolutionary K10 physical esport and Kabuni Premier League unveiled at landmark PLAYTIME 2026 showcase

LONDON, June 08, 2026 (GLOBE NEWSWIRE) -- Black Castle Capital Partners today announced a defining moment for grassroots sport as Kabuni Sports unveiled its AI-powered sports ecosystem at a landmark showcase in Mumbai, bringing together cricket legends, educators, investors, technology leaders and young athletes for one of the most ambitious sports technology events ever staged in India made possible by the fundraising efforts of Black Castle and Kabuni.

Held at the prestigious Jio World Convention Centre in Mumbai, the showcase marked the official launch of Kabuni's AI-powered sports ecosystem and the beginning of a mission to transform how young people learn, play, train and compete through sport.

In front of a packed audience and a global livestream audience spanning multiple countries, Kabuni unveiled:

Kabuni PlayOS - an AI-powered operating system for sport

Kabuni K10 - the world's first PlayOS-powered physical esport

Kabuni Premier League (KPL) - a new competition format designed for the next generation of athletes

The event included an unforgettable live demonstration featuring cricket icons Sourav Ganguly, AB de Villiers, Shane Watson and India T20 Captain Shreyas Iyer, competing alongside grassroots cricketers from Mumbai, demonstrating how technology can help bridge the gap between aspiration and opportunity.

Richard Diaz, CEO of Black Castle Capital Partners, commented:

"The energy in the room was extraordinary. Seeing cricket legends sharing the stage with grassroots players, educators discussing the future of learning, and young athletes interacting with technology that simply did not exist a few years ago was genuinely remarkable.

I left Mumbai more convinced than ever that Kabuni Sports has the potential to become one of the most important sports technology companies to emerge from the UK in the coming decade. For everyone fortunate enough to be in that room, it felt like the beginning of something very special."

A New Chapter for Grassroots Sport

For decades, access to elite coaching, meaningful performance data and structured development pathways has largely been reserved for professional athletes.

Kabuni believes that should change.

The company has spent the last year building an entirely new category at the intersection of artificial intelligence, sports technology, gaming and education.

Its proprietary PlayOS platform combines computer vision, biomechanics, motion tracking, performance analytics and AI coaching to provide young athletes with real-time feedback and personalised development insights.

The result is a platform designed not simply to coach athletes, but to unlock human potential at scale.

The Future of Sport is Play

At the heart of the showcase was Kabuni's central belief:

The battle for attention created screen time.

The opportunity ahead is playtime.

Rather than competing with technology, Kabuni is harnessing it to inspire movement, participation and real-world activity.

Its K10 format transforms training into competition, allowing players to improve through challenges, rankings, leagues and gameplay mechanics powered by real sporting performance.

Every shot played, every ball bowled and every training session completed contributes to a player's digital progression.

It is a model that has the potential to reshape how an entire generation engages with sport.

India Chosen as the First Global Launch Market

Kabuni selected India as the launchpad for its global ambitions for one simple reason.

No nation combines passion for cricket, youth participation and technological adoption at the scale of India.

The company believes the country represents the ideal environment to demonstrate how AI can democratise access to coaching, talent identification and sporting opportunity.

The launch follows the announcement of strategic education partnerships, including White Canvas India, as Kabuni begins building one of the largest school and grassroots sporting ecosystems in the country.

Through the Kabuni Premier League, schools, students and communities will gain access to a connected platform where coaching, competition and talent development operate as a single experience.

A Defining Moment for Kabuni Sports

Yesterday's showcase represented more than a product launch.

It marked the public unveiling of a vision that has been years in the making.

A vision where elite coaching becomes accessible.

Where technology encourages participation rather than inactivity.

Where data enhances development rather than replacing human insight.

And where every child has the opportunity to discover and fulfil their sporting potential.

What began as an ambitious idea has now emerged onto the global stage.

Nimesh Patel, Co-Founder and CEO of Kabuni, said:

"Yesterday was about demonstrating what becomes possible when sport, technology and purpose come together. We believe every child deserves access to great coaching, meaningful competition and the opportunity to realise their potential. Kabuni exists to help make that possible."

Patrick Badenoch, Co-Founder and CFO of Kabuni, added:

"PLAYTIME 2026 was the beginning of something much bigger than a product launch. It was the first step in building a global movement around participation, development and opportunity through sport. The response from athletes, schools, educators and partners has been extraordinary."

The Beginning of an Annual Global Gathering

Kabuni also confirmed that PLAYTIME will become its flagship annual event.

If Apple has WWDC and Salesforce has Dreamforce, Kabuni now has PLAYTIME.

An annual gathering dedicated to the future of grassroots sport, coaching, education, competition and technology.

The company plans to use future editions to unveil new products, partnerships, sports and innovations as its ecosystem continues to expand globally.

Beyond Cricket: Building a Global Multi-Sport Platform

While cricket provides the foundation for Kabuni's initial rollout, the company's ambitions extend far beyond a single sport.

The PlayOS architecture unveiled in Mumbai has been designed as a multi-sport operating system capable of supporting coaching, performance analysis, competition and talent development across a wide range of disciplines.

Following the successful launch of cricket, Kabuni confirmed that development is already underway for additional sports, with golf expected to be the next major sport integrated into the platform.

The company's long-term vision is to create a unified ecosystem where athletes can learn, train, compete and develop across multiple sports through a single AI-powered infrastructure.

By combining computer vision, biomechanics, performance analytics and personalised coaching, Kabuni believes the same technology principles that can transform cricket can ultimately be applied to sports around the world.

From schools and academies to grassroots clubs and aspiring athletes, the opportunity extends far beyond a single market or discipline.

What launched in Mumbai was the first chapter.

The destination is a global sports technology platform capable of supporting millions of athletes across multiple sports, countries and communities.

Nimesh Patel added:

"Cricket is where our journey begins because it provides an incredible opportunity to demonstrate the power of PlayOS at scale. But Kabuni has always been designed as a multi-sport platform. The same technology that can help a young cricketer improve their game can ultimately help athletes across many different sports. Our vision is to build the operating system for grassroots sport globally, and Mumbai was the first major step on that journey."

About Kabuni

Kabuni is building the world's first AI-powered operating system for grassroots sport.

Combining proprietary hardware, computer vision, biomechanics, AI coaching, physical esports and community competition, Kabuni is creating a platform designed to help young athletes train smarter, improve faster and remain engaged through sport.

Founded on a mission to transform screen time into playtime, Kabuni is building technology that inspires movement, coaching, competition and real-world participation at scale.

About Black Castle Capital Partners

Black Castle Capital Partners is a London-based investment consultancy specialising in curated private market opportunities, with a focus on high-growth, technology-driven platforms.

Contact

Black Castle Capital Partners

16 Berkeley Street | Mayfair | London | W1J 8DZ

www.blackcastlecapital.co.uk | admin@blackcastlecapital.co.uk

Black Castle Capital Partners Limited. Registered in England and Wales with Company Number 10635644. Registered Office: 48 Charles Street, Mayfair, London, W1J 5EN

Copyright 2026 GlobeNewswire, Inc.

SCOTTSDALE, Ariz., June 08, 2026 (GLOBE NEWSWIRE) -- Summary

The onsemi Elite Pairing Studio is an online design environment that simplifies pairing SiC MOSFETs and gate drivers for demanding power electronics applications, including AI data centers, electric vehicles, and industrial systems. By providing visibility into device-level behavior and pairing trade-offs, the Studio enables earlier, better-informed engineering decisions and helps reduce design iterations. The Elite Pairing Studio serves as the front door to onsemi's broader suite of design tools, enabling a seamless path to system-level evaluation of performance, efficiency, and thermal behavior.

News Highlights

onsemi's industry-first Elite Pairing Studio helps engineers by analyzing device combinations and recommending well-matched SiC MOSFET and gate driver pairings based on their system requirements

Online tool accelerates development by enabling evaluation of device-level switching behavior, losses, and trade-offs early in the design process, reducing iteration before advancing to full system-level analysis

Interactive, personalized simulation environment gives engineers visibility into timing, waveform behavior, and trade-offs behind each recommended pairing

Additional onsemi technologies will be added to the Elite Pairing Studio in the future

What's New: onsemi today announced its Elite Pairing Studio, an industry-first online design tool that enables engineers to move beyond traditional component-level selection to quickly identify recommended combinations of silicon carbide (SiC) MOSFETs and gate drivers based on their specific requirements. The interactive tool makes it easier to evaluate pairing behavior and trade-offs, helping accelerate the development of power electronics designs. It also serves as the front door to onsemi's broader simulation toolset for system-level performance and efficiency analysis.

Why it Matters: As power electronics grow more complex, engineers must carefully match gate drivers with switching devices to achieve optimal efficiency, minimize losses, and ensure safe operating temperatures. Early component selection decisions have a direct impact on these system-level outcomes, particularly as teams balance competing requirements. Traditionally, this process requires time-consuming manual evaluation and simulation via extensive datasheet comparisons, spreadsheet analysis, and empirical testing.

The onsemi Elite Pairing Studio simplifies this challenge by guiding engineers through a step-by-step process to identify the ideal combination of an onsemi gate driver and SiC MOSFET based on their requirements. Well-matched pairings can be compared quickly, helping reduce iterations and refine power architectures earlier in the development process. This reduces design risk, shortens time to market, and helps ensure systems perform as intended in real-world conditions.

How it Works: The cloud-based environment gives engineers access to a private and secure workspace on onsemi.com where they can use an intuitive workflow to explore device combinations based on their inputs. The tool evaluates a wide range of gate driver combinations with the selected SiC MOSFET, using transparent methods based on established industry equations and real-world performance calculations. The evaluation logic is clear and inspectable for users.

Through the Elite Pairing Studio, engineers can examine key figures of merit for each pairing, including:

Switching timings

Gate voltage and current (V/I) waveforms

Voltage overshoot margins relative to device ratings

Switching energy losses, such as turn-on and turn-off energy

These insights allow engineers to compare pairing trade-offs relevant to their application and gain early visibility into factors that influence electromagnetic interference behavior and reliability margins. Results are visualized through an interactive waveform viewer, enabling more informed pairing decisions before designs are advanced into full system-level simulation. Additional onsemi technologies will be added to the Elite Pairing Studio in the future.

By providing well-matched pairings of SiC MOSFETs and gate drivers tailored to application needs, the onsemi Elite Pairing Studio enables earlier design decisions with a clearer understanding of switching behavior and trade-offs. Those pairing insights can then be carried forward using Studio-generated PLECS system-level simulation models and evaluated in the onsemi Elite Power Simulator to fine-tune efficiency, thermal, and loss performance. Together, this seamless development path helps designers translate early pairing insights into improved system-level efficiency and performance for demanding applications including AI data centers, electric vehicles, industrial systems, and electrification infrastructure.

The onsemi Elite Pairing Studio is available now through the onsemi website and will be demonstrated at the onsemi booth (Hall 9-332) at PCIM Expo 2026 in Nuremberg, Germany.

More Information:

onsemi Elite Pairing Studio: landing page

Related Technologies: onsemi gate driver products, onsemi silicon carbide (SiC) MOSFET portfolio

About onsemi

onsemi (Nasdaq: ON) delivers intelligent power and sensing technologies that enable electrification, energy efficiency, safety, and automation across automotive, industrial, and AI data center end-markets. With a highly differentiated and innovative product portfolio, onsemi helps customers solve complex challenges to achieve higher efficiency, improved performance, and lower system cost, while supporting a safer, cleaner, and more energy-efficient world. The company is part of the S&P 500 index. Learn more at www.onsemi.com.

onsemi and the onsemi logo are trademarks of Semiconductor Components Industries, LLC. All other brand and product names appearing in this document are registered trademarks or trademarks of their respective holders. Although the Company references its website in this news release, information on the website is not to be incorporated herein.

Contact:

Michael Mullaney

michael.mullaney@onsemi.com 

+1 838-289-7314

Copyright 2026 GlobeNewswire, Inc.

Nanterre, June 08, 2026 (GLOBE NEWSWIRE) -- 

Nanterre, June 8, 2026 - North Atlantic France recalls that, on November 28, 2025, it announced the successful closing of its acquisition of 82.89% of the share capital and voting rights of Esso S.A.F, renamed North Atlantic Energies, at a price of EUR26.19 per share.

North Atlantic France announced on November 10, 2025 that it will file a mandatory tender offer under the simplified procedure (the "Offer") for the remaining shares of North Atlantic Energies it does not own at a price of EUR28.93 per share.

North Atlantic France informs the public that it will not request the implementation of a squeeze-out procedure as part of the Offer.

The Offer, therefore with no squeeze-out procedure, will be filed with the Autorit? des march?s financiers (the "AMF") once the independent expert's work has been finalised. The Offer documentation, including the independent expert's fairness opinion on the financial terms of the Offer, will be submitted to the AMF for review, and the Offer will only open once the AMF has issued its compliance decision.

MEDIA CONTACTS

France: Brunswick Group - northatlantic@brunswickgroup.com

Hugues Bo?ton: +33 6 79 99 27 15

Paul Priam: +33 6 84 39 09 89

Canada: Mark Duggan - markduggan@northatlantic.ca

+1-709-687-3136

ABOUT NORTH ATLANTIC

For nearly four decades, North Atlantic has been a market leader in the retail gas and convenience sector, as well as the residential, commercial, and wholesale fuel industries in Newfoundland and Labrador. Recently, through a joint venture with Suncor Energy, North Atlantic expanded its retail division into Nova Scotia and Prince Edward Island, through North Sun Energy. As managing partner, North Atlantic operates 110 fuel retail sites across all three provinces. North Atlantic has ambitious plans for future growth and development in strategic locations across the region. Known for its expertise in acquiring and delivering exceptional products, North Atlantic caters to both domestic and industrial sectors while also serving global clients through their marine bunkering distribution channels. North Atlantic is committed to strategic growth to deliver innovative and green energy solutions aligned with evolving global needs. By driving industry progress, North Atlantic is supporting new skills and new jobs for this dynamic landscape. North Atlantic remains committed to providing exceptional energy, fuel and convenience retail initiatives that enhance customer experience while fostering economic growth in the communities they serve in Canada and beyond.

MEDIA CONTACTS

France: Brunswick Group - northatlantic@brunswickgroup.com

Hugues Bo?ton: +33 6 79 99 27 15

Paul Priam: +33 6 84 39 09 89

Canada: Mark Duggan - markduggan@northatlantic.ca

+1-709-687-3136

Copyright 2026 GlobeNewswire, Inc.

2,000 global leaders and experts, and 25,000 trade visitors expected to share best practices, exchange ideas, foster partnerships and secure deals

SINGAPORE - Media OutReach Newswire - 8 June 2026 - The Singapore International Water Week (SIWW) 2026 will bring together thought leaders, experts and practitioners from governments, cities, utilities and industry from 15 to 18 June 2026 at the Sands Expo and Convention Centre in Singapore to address some of the world's most pressing urban water and climate-associated challenges.

Now in its 11th edition, the biennial event takes place against the backdrop of utilities and cities facing mounting pressure on aging urban water systems, higher energy costs, increasing water demand, unsustainable water extraction practices, and more frequent and extreme flooding in urban areas. Caused by rapid urbanisation and economic growth, these effects are further exacerbated by climate impacts from extreme weather patterns and rising sea levels, and growing demand from water-intensive industries such as data centres.

Addressing these challenges would require governments to adopt a holistic and integrated approach in water management, coupled with good governance, effective policies and regulations, adoption of innovative technological solutions, and active engagement of stakeholders.

To this end, SIWW2026 will focus on triple key themes of municipal water solutions, coastal and flood resilience, and industrial water solutions. In total, more than 80 sessions - ranging from high-level panels, roundtables, summits, workshops, forums and partner events - will be held over 4 days covering a wide spectrum of topics and issues related to these themes, with 2,000 global leaders and experts expected in attendance, along with 25,000 trade visitors who are expected to visit the Water Expo.

SIWW2026 at a Glance: Key Programme Highlights

Guest-of-Honour, Mr Gan Kim Yong, Singapore's Deputy Prime Minister and Minister for Trade and Industry, will deliver the opening address at the opening of SIWW2026 on Tuesday, 16 June 2026. This will be followed by the Lee Kuan Yew Water Prize 2026 Award Ceremony, where the 2026 Laureate Professor Joan Bray Rose will receive the Prize medallion and certificate from Mr Gan.

The Ministerial Plenary will be held on the same morning after the opening, where Ms Grace Fu, Singapore's Minister for Sustainability and the Environment and Minister-in-charge of Trade Relations, will join other invited foreign Water and Environment Ministers to share their perspectives on how countries can work together to advance the water and climate agenda.

Other programme highlights at SIWW2026 include:

Thought Leadership:High-level platforms such as the SIWW Keynotes, Titans of Industry, Coastal and Flood Resilience Leaders Summit, and the Water Leaders Summit will bring together global government, city, utility and industry leaders to exchange insights on latest trends, solutions, and case studies across various thematic areas.

Solutions and Technology: The Water Convention, TechXchange, and the Industrial Water Solutions Forum will provide water experts, technology providers, scale-ups, utilities and industrial users with platforms to share urban water management, for municipal and industrial users.

Business and Networking: The Water Expo, organised in cooperation with IFAT, will serve as a pre-eminent marketplace for the global water, coastal and flood community to converge and find opportunities in business. Featuring more than 20 pavilions and close to 500 international exhibitors, the Expo - alongside networking functions and partner events - will bring together industry players, utilities and governments to foster collaboration and partnerships.

Distinguished Leaders from Utilities, Cities and Industry at SIWW2026

More than 55 utilities around the world, including the USA, Europe, Middle East, Australia and Asia, will be participating in SIWW2026, with at least 40 represented at C-level. These senior executives will be attending the Utilities CEO Roundtable, while technical experts will be speaking in other sessions and workshops during the week.

These utilities would be joined by close to 30 cities worldwide, including Copenhagen, Rotterdam, Hong Kong, New York City, Antwerp, Dubai, Jakarta, Melbourne, Quezon City, Tokyo and Yokohama. City officials from these cities would be participating in the City Leaders Roundtable, as well as Leaders Summit.

Senior leaders from international organisations and associations, such as the Intergovernmental Panel on Climate Change (IPCC), Asian Development Bank, World Bank Group, C40 Cities, International Water Association, International Desalination and Reuse Association will also be in attendance. They are joined by global executives and experts from the water industry, including engineering consultants, technology providers, system integrators contractors, and OEMs.

For more information on SIWW2026, visit the event website at www.siww.com.sg/home or access the full programme at siww2026-app.siww.com.sg

SIWW is part of the strategic programme of the Singapore Government to grow the water industry and develop water technologies. The event also supports Go Green SG and Singapore's Year of Climate Adaptation, reinforcing collective action towards sustainability and climate resilience.

About the Singapore International Water Week

Singapore International Water Week (SIWW) is one of the world's premier platforms to share and co-create innovative water, coastal and flood solutions to meet urban water and associated climate challenges.

Organised by Singapore International Water Week Pte Ltd, a subsidiary of PUB, Singapore's National Water Agency, the biennial SIWW delivers a range of flagship programmes and platforms that gathers stakeholders from governments, cities, utilities, academia, and industry to share best practices and solutions, showcase the latest technologies and harness business opportunities.

The 11th Singapore International Water Week will be held from 15 to 18 June 2026.For more information, visit www.siww.com.sg

The issuer is solely responsible for the content of this announcement.

Hashtags: #SingaporeInternationalWaterWeek #SIWW2026

Devilla BESS is a 500MW construction-stage battery project that, upon commissioning in 2028, is set to become one of the biggest of its kind in Europe.

COPENHAGEN, Denmark and EDINBURGH, Scotland, June 08, 2026 (GLOBE NEWSWIRE) -- Copenhagen Infrastructure Partners (CIP), on behalf of Copenhagen Infrastructure IV (CI IV), has agreed to divest minority stakes in the Devilla battery storage project to the Scottish National Investment Bank ("the Bank") and Nuclear Liabilities Fund (NLF). Once operational, the project will be among Europe's largest battery storage facilities, supporting grid stability and the integration of renewable energy generation.

Devilla is a 500MW, 2-hour-duration, lithium-ion battery energy storage system (BESS) located in Kincardine, Scotland. CIP retains the majority stake and will continue to lead project delivery through the current construction phase. The project has a high level of contracted revenues through a 10-year optimisation agreement with SSE plc, a leading generator of renewables and flexible power in Great Britain and Ireland, alongside a 15-year capacity market agreement, providing visibility and a stable foundation for returns while maintaining exposure to market upside.

Devilla is one of three transmission-connected BESS assets co-developed by Alcemi and CIP that are currently being constructed by CIP in Scotland. Collectively, the projects will have a total power capacity of 1.5GW and will be able to store and supply the grid with a total of 3GWh of electricity, enough to supply over 4.5 million households for two hours. CIP is developing a further 4.5GW of BESS projects across Scotland and England.

Commenting on the news, Nischal Agarwal, Partner at CIP, said: "As CIP's development and construction portfolio of UK BESS projects continues to progress and grow, we look forward to welcoming the Scottish National Investment Bank and Nuclear Liabilities Fund as new equity partners on our Devilla site. Once commissioned in 2028, Devilla will be one of Europe's biggest operational BESS projects. The delivery of Devilla, alongside CIP's Coalburn 1 and 2 projects, will improve the UK's energy security and reduce costs for British consumers through enhanced system flexibility and access to more low-cost renewables."

Robin Tayal, Investment Director at the Scottish National Investment Bank, said: "Battery energy storage systems are a critical part of improving energy security and stability. The Devilla site is strategically located and will support renewable integration, grid stability, and system flexibility. We are pleased to partner with CIP and the wider investor group to support the delivery of this important asset."

Melissa Hope, Chief Executive of Nuclear Liabilities Fund, added: "NLF is pleased to partner with CIP and the Bank on this battery storage project. This investment aligns with our strategic investment objectives while supporting UK energy security and economic growth."

Notes to Editors

Media Contact

CIP: media@cip.com

Scottish National Investment Bank: thebank@charlottestreetpartners.com

NLF: info@nlf.uk.net

About Copenhagen Infrastructure Partners

Founded in 2012, Copenhagen Infrastructure Partners P/S (CIP) is a global fund manager and leading investor in energy infrastructure. CIP builds value that matters by developing and constructing critical infrastructure projects that shape the future of energy. Through its funds, CIP invests in power generation (solar and wind), energy storage, transmission and distribution, advanced bioenergy, low-carbon fuels and carbon capture.

With 15 funds currently under management, CIP is trusted by over 200 of the world's largest and most sophisticated institutions, having raised EUR ~37 billion to date. CIP has projects in more than 30 countries, with presence on the ground through a network of +2,300 professionals.

For more information, visit www.cip.com.  

About the Scottish National Investment Bank 

The Scottish National Investment Bank is Scotland's development bank and exists to provide patient (long-term) debt or equity investments to businesses and projects that support the development of a fairer, more sustainable Scottish economy.

The Bank is a public limited company (plc) that was established in November 2020. It is wholly owned by Scottish Government ministers on behalf of the people of Scotland, but operates independently from government.

  

As an impact investor, the Bank is focused on delivering both commercial returns and tangible benefits that align with at least one of its three missions:

Net zero: Addressing the climate crisis through growing a fair and sustainable economy  

Innovation: Scaling up innovation and technology for a more competitive and productive economy  

Place: Transforming communities to make them places where everyone thrives.  

The Scottish Government has committed to capitalising the Bank with ?2bn in its first 10 years. Over time, as the Bank's initial investments are repaid, it will reinvest those funds in more businesses and projects, creating a perpetual investment fund to support the Scottish economy in the long term.

Find out more at: www.thebank.scot   

About the Nuclear Liabilities Fund

Established in 1996, the Nuclear Liabilities Fund (NLF) is an independent ring-fenced fund to meet the costs of decommissioning eight nuclear power stations in the UK. To date circa ?2.8bn of decommissioning payments have been made. The decommissioning programme is expected to continue into the next century, with NLF protecting both current and future generations from costs associated with generation of nuclear power. NLF assets are invested to optimise growth and achieve returns to meet the fund's long-term obligations. NLF contributes to the UK economy with over ?1.6bn invested in the UK.

Further information can be found on www.nlf.uk.net

Copyright 2026 GlobeNewswire, Inc.

Cyberjaya campus integrates Malaysia into Digital Realty's global network, enabling customers to deploy AI and data-driven workloads across a connected infrastructure

KUALA LUMPUR, Malaysia, June 08, 2026 (GLOBE NEWSWIRE) -- Digital Realty (NYSE: DLR), the world's largest cloud- and carrier-neutral data center platform, today announced the establishment of its Malaysia platform, marking a key milestone in its Asia Pacific expansion. The company has planned to develop and scale its data center capacity in Malaysia to approximately 32 megawatts (MW), integrating Malaysia into its global platform designed for interconnection, resilience and scale.

The milestone was commemorated at an inauguration ceremony officiated by YB Gobind Singh Deo, Minister of Digital for Malaysia, Ms. Zuaida Abdullah, Deputy Chief Executive Officer, Investment Development, Malaysian Investment Development Authority (MIDA), En. Wan Murdani, Senior Vice President, Malaysia Digital Economy Corporation (MDEC), alongside Digital Realty leadership including Serene Nah, Managing Director and Head of Asia Pacific, Govind Choudhary, General Manager, Southeast Asia and India, and Billy Lee, Chairman, CSF Advisers Sdn Bhd & Advisor for Digital Realty in Malaysia.

The event signals Digital Realty's commitment to supporting Malaysia's ambition to become a leading digital infrastructure and AI hub in Southeast Asia. Anchored in Cyberjaya, the campus is purpose-built to support Malaysian enterprises of all sizes as they evolve from traditional IT environments to hybrid architectures and AI-driven use cases. Planned as a multi-site deployment, the campus will span three facilities, all connected via dedicated fiber.

KUL10 (formerly TelcoHub 1) - An operational, carrier-dense facility with 1.5MW of IT capacity and *one of the most connected data center ecosystems in Malaysia. Digital Realty plans to upgrade the facility to its global standards, expecting to nearly double capacity by Q4 2027.

KUL11 - Located approximately 500 meters from KUL10, this is a newly acquired, purpose-built data center with 15MW of IT capacity, designed to support AI and high-performance computing workloads. The facility incorporates energy- and water-efficient design principles to support sustainable digital infrastructure growth.

Future expansion site - An adjacent 1.6-acre land parcel located approximately 200 meters from KUL10, where, Digital Realty plans to develop a new 14MW data center. Targeted for completion in mid-2028, the facility is planned to be built to Digital Realty's global standards and designed to support hybrid colocation and AI-ready deployments.

Together, these assets will form a highly connected platform, to be supported by more than 40 network service providers, alongside a robust ecosystem of cloud and connectivity partners.

Since announcing our planned entry into the Malaysian market in January, Digital Realty has established a multi-site presence in Cyberjaya. This rapid build-out underscores the company's strong conviction in Malaysia's long-term role as a regional digital hub and reflects a disciplined strategy of scaling both capacity and connectivity.

These developments establish the foundation of Digital Realty's growing platform in Malaysia, which will enable enterprises, including cloud and digital businesses to deploy and scale infrastructure within a globally connected data community. By integrating its Cyberjaya facilities into PlatformDIGITAL and enabling interconnection through ServiceFabric, Digital Realty will support distributed, AI and data-intensive workloads requiring low-latency, high-performance connectivity across markets.

Customers in Malaysia can gradually connect to Digital Realty's global ecosystem of more than 300 data centers across 30+ countries, enabling low-latency connectivity and seamless workload deployment across key regional hubs including Singapore and Jakarta.

YB Gobind Singh Deo, Minister of Digital for Malaysia, said, "Digital Realty's investment marks an important step in strengthening Malaysia's position as a sovereign, interconnected and sustainable digital infrastructure hub. As demand for cloud, AI and data-driven services continues to accelerate, the development of high-quality, globally connected data center infrastructure will be critical in supporting innovation, attracting investment, and enabling Malaysia's digital economy to grow with resilience and scale. Investments in advanced digital infrastructure such as this are essential to supporting Malaysia's AI ambitions and strengthening our position as a regional innovation hub."

"As demand for AI and data-driven services grows, investments in globally connected digital infrastructure are becoming increasingly important in driving innovation, strengthening regional connectivity and raising Malaysia's visibility in the global digital economy. Beyond infrastructure, these investments support a wider digital ecosystem that enables businesses to innovate, scale and participate more effectively in regional and global digital value chains. Through the Malaysia Digital (MD) national strategic initiative, MDEC remains focused on attracting catalytic digital investments that strengthen the ecosystem, create high-value opportunities and advance Malaysia's aspiration of becoming an AI Nation by 2030," said Malaysia Digital Economy Corporation (MDEC) Chief Executive Officer, Anuar Fariz Fadzil.

Serene Nah, Managing Director and Head of Asia Pacific, Digital Realty, said, "The establishment of our Malaysia presence marks an important milestone in Digital Realty's Southeast Asia expansion. As digital adoption accelerates and AI-driven workloads become more distributed and latency-sensitive, customers require infrastructure that is scalable and deeply interconnected.

"Malaysia plays a key role as an interconnection hub within our regional footprint, enabling customers to seamlessly deploy and manage workloads across markets. By integrating our Cyberjaya facilities into PlatformDIGITAL, we will extend a connected data community that spans key hubs such as Singapore and Jakarta. The speed at which we have established a multi-site presence reflects strong customer demand and our long-term commitment to supporting Malaysia's digital growth."

Billy Lee, Chairman of CSF Advisers Sdn Bhd and Advisor for Malaysia, Digital Realty, said, "TelcoHub 1 was built to be one of Malaysia's most connected data center facilities, trusted by a diverse ecosystem of enterprises, carriers and cloud providers. Becoming part of Digital Realty enables us to take this foundation further by integrating into a global interconnection platform that spans more than 300 data centers worldwide.

"This evolution delivers immediate value to our customers, who will be able to access a broader interconnection ecosystem and scale their infrastructure beyond Malaysia with greater flexibility. At the same time, our local team remains at the core of this journey, now strengthened by Digital Realty's global expertise, operational discipline and long-term investment approach."

Digital Realty's presence in Malaysia supports a diverse ecosystem of cloud providers, enterprises and network service providers, enabling them to expand and interconnect across the region. The company also plans to grow its local team to support continued operational scale and ecosystem development.

All facilities are designed with a focus on energy-efficient and scalable operations, supporting responsible data center growth in line with Malaysia's sustainability priorities. This expansion strengthens Malaysia's role in enabling cross-border data flows and supporting next-generation digital services, while reinforcing Digital Realty's broader Asia Pacific footprint across key markets including Singapore and Jakarta.

About Digital Realty

Digital Realty brings companies and data together by delivering the full spectrum of data center, colocation, and interconnection solutions. PlatformDIGITAL, the company's global data center platform, provides customers with a secure data meeting place and a proven Pervasive Datacenter Architecture (PDx) solution methodology for powering innovation, from cloud and digital transformation to emerging technologies like artificial intelligence (AI), and efficiently managing Data Gravity challenges. Digital Realty gives its customers access to the connected data communities that matter to them with a global data center footprint of 300+ facilities in 55+ metros across 30+ countries on six continents. To learn more about Digital Realty, please visit digitalrealty.com or follow us on LinkedIn and X.

For Additional Information

Media Contacts

Joyce Ng

Digital Realty

jong@digitalrealty.com

Investor Relations

Jordan Sadler / Jim Huseby

Digital Realty

+1 (737) 281-0101

InvestorRelations@digitalrealty.com

Safe Harbor Statement

This press release contains forward-looking statements which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially, including statements related to PlatformDIGITAL?, the company's strategy, expected completion dates, customer demand and expectations for the Asia Pacific region and sustainability goals. For a list and description of risks and uncertainties, see the reports and other filings by the company with the U.S. Securities and Exchange Commission. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

________________

*Source: PeeringDB, 2026

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/09e784ca-ab6e-4c2b-b352-a5b6a021c72b

Copyright 2026 GlobeNewswire, Inc.

Partnership with the Countries' Largest Tech Parks to Propel "Hub-to-Hub" Collaborations Supporting HK and Chinese Mainland Enterprises to Tap Central Asian Markets

HONG KONG SAR - Media OutReach Newswire - 8 June 2026 - Simon Chan, Chairman of Cyberport, joined the business delegation led by Chief Executive John Lee, on a visit to Kazakhstan and Uzbekistan from 1 to 5 June 2026 to strengthen innovation technology (IT), economic and trade cooperation between Hong Kong and the Central Asia.

During the visit, Cyberport signed Memoranda of Understanding (MoUs) with leading technology organisations in both Kazakhstan and Uzbekistan, establishing strategic partnerships with the two countries' key innovation and technology platforms and promoting "hub-to-hub" collaboration to jointly capture opportunities in emerging markets.

As part of the programme, Simon Chan, Chairman of Cyberport, met with key innovation and technology stakeholders in both countries. He visited the Astana Hub, a local technology and innovation park in Kazakhstan, including its Artificial Intelligence Supercomputing Centre, to gain deeper insights into the latest developments in artificial intelligence and digital infrastructure in the region. He also visited IT Park Uzbekistan to learn more about the country's rapidly growing digital economy ecosystem, and to explore opportunities for deeper collaboration in innovation and technology development, talent cultivation and market expansion. These engagements further strengthened Hong Kong's exchanges with Central Asia and supported the development of closer cross-regional collaboration in innovation and technology.

Simon Chan, Chairman of Cyberport, said, "Central Asia is a strategically important market under the Belt and Road Initiative. Both Kazakhstan and Uzbekistan are actively advancing digital transformation, digital upgrading and technological innovation. From national artificial intelligence development blueprints to large-scale digital infrastructure projects, both countries have demonstrated strong growth momentum, a pressing demand for cutting-edge innovation and technology solutions, and immense market potential.

As Hong Kong's digital technology hub and AI accelerator, Cyberport is home to over 2,300 companies, including 18 listed companies with a combined market capitalisation of over HK$500 billion, as well as 9 unicorns with a total valuation exceeding HK$150 billion. Its innovation ecosystem spans areas such as AI, data science, fintech, digital assets and blockchain, cybersecurity, smart living, and digital entertainment. This aligns closely with Central Asia's demand for technological innovation, creating extensive opportunities for collaboration through complementary strengths. Cyberport has also established partnerships with Astana Hub and IT Park Uzbekistan to actively promote bilateral business expansion, deepen ties between Hong Kong and Central Asia in innovation and technology, finance and trade, and support enterprises from Hong Kong and the Mainland in jointly expanding into high-potential emerging markets.

Leveraging Hong Kong's unique role as a 'super-connector' and 'super value-adder', Cyberport will continue to support Hong Kong and Mainland enterprises in expanding into Belt and Road and international markets. At the same time, we will actively attract Central Asian companies to establish a presence in Hong Kong, injecting fresh momentum into the development of the digital economy and smart cities across the three regions, and further strengthening Hong Kong's position as an international innovation and technology centre and a leading AI hub."

Simon Chan, Chairman of Cyberport, said, "Central Asia is a strategically important market under the Belt and Road Initiative. Both Kazakhstan and Uzbekistan are actively advancing digital transformation, digital upgrading and technological innovation. Cyberport has established partnerships with Kazakhstan Astana Hub and IT Park Uzbekistan to actively promote bilateral business expansion, deepen ties between Hong Kong and Central Asia in innovation and technology, finance and trade, and support enterprises from Hong Kong and the Mainland in jointly expanding into high-potential emerging markets."

Signs MoUs with the Countries' Largest Tech Parks Leveraging "Hub-to-Hub" Collaboration Advantages

Among them was a Memorandum of Understanding (MoU) signed on 1 June 2026 between Cyberport and Autonomous Cluster Fund "Astana Hub" (Astana Hub) of Kazakhstan, the largest international innovation cluster in Central Eurasia. Astana Hub is currently home to more than 1,800 IT companies, including over 450 international members, generating a collective income of US$3.9 billion. It has established a comprehensive innovation ecosystem that provides acceleration programmes, supports technological business incubation, offers educational initiatives, and hosts a wide range of industry events. This strategic partnership aims to promote technology transfer, support tech companies in areas such as AI, fintech, smart city solutions and Web 3, and facilitate overseas expansion and global market access for innovation and technology companies from both regions.

Another key highlight of the delegation was the signing of a Memorandum of Understanding (MoU) on 4 June 2026 between Cyberport and The Administration of Technology Park of Software and IT (IT Park) of Uzbekistan, a national IT ecosystem operator dedicated to advancing the country's digital industry development. IT Park Uzbekistan is a government-supported technology hub and one of the largest tech parks in Central Asia, with more than 2,800 member companies spanning IT services, software development, game development, creative industries and education. The MoU focuses on providing mutual soft-landing support, infrastructure access and regulatory incentives to facilitate technology companies' expansion between Hong Kong and Central Asian markets, while fostering deeper collaboration in innovation and technology development between the two regions.

As an ideal gateway for Central Asian technology companies seeking to expand into East and Southeast Asia, Cyberport leverages Hong Kong's international business environment and robust regulatory framework, together with its extensive network of enterprises, investors, technology companies, professional service providers and industry partners. This enables Cyberport to serve as a strategic base for Central Asian enterprises looking to access the Mainland, ASEAN, Asia-Pacific and global markets, accelerating their commercialisation journey and transforming innovative solutions into tangible business collaborations and investment opportunities.

At the same time, Cyberport companies can leverage the two leading technology parks in Central Asia as launchpads into emerging markets, bringing technology solutions from Hong Kong such as artificial intelligence, fintech and smart city technologies to support the region's digital economy and smart city development. These collaborations will further enrich the innovation and technology ecosystems of both regions. Cyberport has been actively supporting local enterprises in establishing and expanding their presence in Central Asian market. Cyberport's community is also highly international, with founders of one-third of its onsite companies coming from 27 countries and regions, while Cyberport companies have expanded into more than 35 global markets.

Cyberport received delegations from Kazakhstan and Uzbekistan to Cyberport for exchanges in tech innovation and entrepreneurship over the past year, laying foundations for cross-regional partnerships and collaborations. Cyberport will continue to align with the national 15th Five-Year Plan and support the HKSAR Government's development strategies by strengthening ties with emerging markets and innovation and technology hubs along the Belt and Road. As a vital bridge between Hong Kong and Central Asia, Cyberport facilitates cross-regional exchanges and collaboration, helping local enterprises capture global business opportunities while simultaneously attracting outstanding overseas technology talent and leading enterprises to establish a presence in Hong Kong. These efforts will inject diversified momentum into Hong Kong's economy and further reinforce the city's position as an international innovation and technology hub.

About Hong Kong Cyberport

Wholly owned by the Hong Kong Special Administrative Region (HKSAR) Government, Cyberport is Hong Kong's digital tech hub and AI accelerator, with a vision to empower industry digitalisation and intelligent transformation, to promote digital economy and AI development, and to foster Hong Kong to be an international AI, innovation and technology (I&T) hub. Cyberport gathers over 2,300 companies, including 18 listed companies and 9 unicorns. One-third of onsite companies' founders come from 27 countries and regions, while Cyberport companies have expanded to over 35 global markets.

Cyberport, with Hong Kong's largest AI Supercomputing Centre and AI Lab as the engine, has been building the AI ecosystem with industry-leading AI companies and over 500 AI and data science start-ups. Through development of tech clusters, namely AI, data science, blockchain and cybersecurity, Cyberport empowers industries across smart city and government, banking and finance, digital entertainment, culture and tourism, healthcare, education and training, property management, construction, transportation and logistics, green environment and more, while hosting Hong Kong's largest FinTech community. Commissioned by the HKSAR Government, Cyberport has implemented proof-of-concept and sandbox schemes, subsidisation for digital tech adoption, industry tech training and start-up incubation, to drive technology R&D, translation and commercialisation, thus propelling digital transformation and intelligent upgrade across industry and society.

Also as "State-level Scientific and Technological Enterprise Incubator" and Hong Kong's key incubator, Cyberport supports entrepreneurs with funding and office space, extensive networks of enterprises, investors, technology corporations and professional services for business growth and expansion to Chinese Mainland and overseas markets, all-round facilitation for landing in Hong Kong, talent attraction and cultivation, ready as a launchpad to take start-ups in any stages of development to the next level.

For more information, please visit https://www.cyberport.hk/en

The issuer is solely responsible for the content of this announcement.

Hashtags: #Cyberport

Partnership combines LINE GO's MaaS ecosystem platform with Trransfer Technologies' global B2B ground transportation platform to serve Taiwan's growing outbound business travel demand

SINGAPORE - Media OutReach Newswire - 8 June 2026 - Trransfer Technologies, a global B2B ground transportation platform serving corporate travel managers, private aviation firms, banks, luxury concierge services and enterprise customers to fulfill across more than 80 destinations worldwide, announced the official launch of its strategic partnership with LINE GO, Taiwan's premier MaaS (Mobility as a Service) ecosystem platform.

Officially commencing today, the partnership follows a successful one-month operational pilot since May 11, 2026, and is designed to unlock new enterprise demand in Taiwan while creating a scalable outbound travel solution for Taiwanese companies, multinational corporations and business travelers.

Taiwan's outbound travel market reached 18.94 million departures in 2025, a 12.43 percent increase from 2024 and a new historical high. This upward trajectory underscores a compelling opportunity for enterprise-focused mobility providers to capture demand from corporations and business travelers who require seamless, reliable ground transportation solutions across global destinations.

A Partnership Built on Complementary Strengths

Trransfer Technologies will bring international corporate and enterprise travel demand into Taiwan, with LINE GO providing local fulfillment through its established mobility network, operational capabilities and deep integration within the LINE ecosystem. LINE GO's MaaS platform aggregates seven mobility services including taxi-hailing, car rentals, airport shuttles, designated driver services, scooter sharing, private car charters and an EV charging network, giving enterprise clients a comprehensive local mobility experience upon arrival in Taiwan.

Looking ahead, both companies will extend their collaboration to serve the outbound travel needs of Taiwan-based enterprises, leveraging Trransfer Technologies' global destination network across more than 80 destinations worldwide. This positions both companies to become the preferred mobility partner for Taiwanese businesses and multinationals requiring end-to-end ground transportation coordination across borders.

Targeting Taiwan's Enterprise Traveler Segment

The partnership specifically targets multinational corporations, corporate travel managers, enterprise clients and high-frequency business travelers. As Taiwan's outbound travel continues its upward trajectory, enterprises increasingly need partners who understand both local logistics and the complexity of global coordination.

"This partnership creates immediate strategic value for both companies. LINE GO brings market-leading mobility technology and operational insights, while Trransfer Technologies contributes the global platform, enterprise workflows and international fulfillment network. Together, we are building a scalable outbound mobility solution for Taiwanese enterprises traveling globally."

Michael Chiay, Chief Executive Officer, Trransfer Technologies

"This collaboration marks a transformative milestone in LINE GO's journey. We are proud to offer our partners a one-stop solution that delivers on our promise to make every journey smarter, safer, and more efficient."

Isaac Lin, Managing Director, LINE GO

About Trransfer Technologies

Trransfer Technologies is a global B2B ground transportation platform connecting corporate travel managers, private aviation firms, banks, luxury concierge services and enterprise customers with local ground transportation operators to fulfill across more than 80 destinations worldwide. The company provides a unified platform designed to simplify business travel mobility, improve supplier coordination and support seamless ground transportation fulfillment across markets.

For more information, please visit www.trransfer.com.

About LINE GO

LINE GO is Taiwan's premier MaaS platform offering taxi-hailing, car rentals, airport shuttles, designated driver services, scooter sharing, private car charters and an EV charging network, all within the LINE ecosystem. In 2025, LINE GO achieved dual ISO 27001 and ISO 27701 certifications, underscoring its commitment to world-class information security and data privacy.

The issuer is solely responsible for the content of this announcement.

*Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity

*News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP-1 dual agonist, from baseline.1 ​

*Detailed pre-specified analysis from a sub study of SYNCHRONIZE-1 show that, relative to baseline, survodutide achieved a reduction of up to 34% in visceral fat, with the proportion of lean mass loss reflecting no more than 10.8% of change in total tissue mass at the highest dose, alongside an up to 63.1% reduction of liver fat, indicating a targeted reduction in metabolically harmful fat after 76 weeks.2,3

*Detailed results presented from SYNCHRONIZE-MASLD, showed that the trial met both its primary endpoints, with additional results showing that, relative to baseline, liver fat normalization was reached by 6 out of 10 participants living with metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity or overweight who were treated with survodutide after 48 weeks.4

*The SYNCHRONIZE-1 and SYNCHRONIZE-MASLD results were presented at the American Diabetes Association's (ADA) 2026 Scientific Sessions and simultaneously published in The New England Journal of Medicine and Nature Medicine, respectively.5,6

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide's potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association's (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

SYNCHRONIZE-1 Results

The 76-week Phase III SYNCHRONIZE-1 trial investigated survodutide in adults living with obesity or overweight, without type 2 diabetes. Positive topline data announced in April showed that the trial met its primary endpoints using both the treatment-regimen* and efficacy? estimands.1 Sustained weight loss of up to an average of 16.6% was seen using the efficacy estimand, a statistically significant decrease versus 3.2% in the placebo arm (p<0.0001).2? 

In a sub study of the trial the fat loss observed in the patients who provided MRI measurements at baseline and end of study while on treatment, showed a relative reduction of up to 34.0% visceral fat.2 Additional analysis showed that lean mass accounted for no more than 10.8% of change in total tissue mass at the highest dose, indicating that weight loss was primarily driven by reductions in fat mass.2 In the same sub study, a pre-specified analysis showed adults treated with survodutide had liver fat reduction of up to 63.1% further demonstrating survodutide's potential to positively impact metabolic health.2 

"For people living with obesity, weight loss is only one part of the story. They face an increased risk of developing serious conditions driven by obesity and associated metabolic dysfunction, including metabolic liver disease, type 2 diabetes, and cardiovascular disease. There is an urgent need for treatments that go beyond weight loss to also address these related conditions," Dr Lee Kaplan, M.D., Ph.D., Director of The Obesity and Metabolism Institute, Boston, MA, USA, Chair of the SYNCHRONIZE program executive committee said. "I am delighted to see that these data reveal that the glucagon/GLP-1 dual agonism of survodutide offers a promising approach for people with obesity, and for those with obesity-associated metabolic liver diseases including MASLD and MASH."   

"Obesity is a complex disease linked to how the body manages metabolism. Excess visceral fat, which is found primarily around the abdomen, is a known contributor to metabolic dysfunction and is closely connected to impaired liver function," said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma, Boehringer Ingelheim. "By tackling obesity alongside visceral fat and liver fat, survodutide has the potential to redefine what a targeted weight management therapy can achieve, as we aim to address key drivers of metabolic dysfunction often associated with obesity."

Metabolic health refers to how the body processes nutrients and maintains homeostasis.7 As a complex disease, obesity goes beyond weight, having associations with disruptions in metabolic processes.8 Up to three in every four people living with obesity have MASLD, where excess fat builds up in the liver.9 For about one in three people living with obesity, this can advance to a more serious stage called metabolic dysfunction-associated steatohepatitis (MASH), which is characterized by inflammation and liver damage.9 

SYNCHRONIZE-MASLD results

Positive Phase III results from the SYNCHRONIZE-MASLD trial further reinforce survodutide's potential in metabolic health by demonstrating improvements in weight loss and a targeted reduction in liver fat.4 The SYNCHRONIZE-MASLD trial investigated survodutide for 48 weeks among adults with obesity or overweight who had MASLD with evidence of inflammation and or fibrosis, both with and without type 2 diabetes.4 

The trial met its co-primary endpoints using both the treatment-regimen and efficacy estimands, with results showing that up to 84.2% of participants treated with survodutide experienced at least a 30% relative liver fat reduction using the efficacy estimand, a statistically significant improvement over 24.3% in the placebo arm (p<0.0001).4 The trial met its other co-primary endpoint with a relative reduction in body weight of up to 12.2%, using the efficacy estimand versus 1.0% in the placebo arm (p<0.0001).4 Additional detailed results, from a secondary endpoint, showed up to 6 out of 10 patients (61.0%) reached liver fat normalization (liver fat content <5%) at Week 48 using the efficacy estimand, versus 5.7% in the placebo arm.4 

Positive trends were also observed across other secondary endpoints evaluating liver-related biomarkers, such as alanine transaminase (ALT) levels, signaling reduction in inflammation.4 

As expected with GLP-1 based therapies, in SYNCHRONIZE-1 the most commonly reported adverse events for survodutide were gastrointestinal (GI) events, which were mostly mild to moderate in severity and usually occurring during the dose escalation phase.2 The more frequent events included nausea, vomiting, diarrhea, and constipation compared with placebo.2 The treatment discontinuation rates due to GI adverse events were 19% in people treated with survodutide compared to 2.9% on the placebo arm.2 These results were consistent across the SYNCHRONIZE-MASLD trial and with the known class effects. No new safety signals were identified in both trials.4 Looking ahead, Boehringer is committed to helping patients and clinicians make informed decisions through more optimized, patient centered dosing guidance and protocols.

Collectively, SYNCHRONIZE-1 and SYNCHRONIZE-MASLD show the potential benefits of glucagon/GLP-1 dual agonism for people living with obesity and people with MASLD with evidence of inflammation and or fibrosis.2,4,10 Survodutide could address the unmet need for treatment of these conditions as its GLP‑1 agonism decreases appetite while increasing fullness and satiety,11 while its glucagon agonism is thought to directly act on the liver to reduce hepatic fat, regulate metabolic function, resolve inflammation, and improve fibrosis.12,13,14 Survodutide is an investigational agent and has not been approved for use; its efficacy and safety have not been established.

Additionally, as part of the broader evidence program, a set of Phase IIIb studies are being advanced to address key unmet needs in people living with obesity and real-world care. Initiating later this year, SYNCHRONIZE-HERA will evaluate survodutide in women's health; ELEVATE-LIVER will assess the impact of survodutide in the preservation of cardiac function and structure in people living with MASLD or early MASH; and SYNCHRONIZE-START will examine real-world titration approaches, including treatment initiation and switching from GLP-1 RAs, with a focus on tolerability. These efforts complement SYNCHRONIZE-1 and SYNCHRONIZE-MASLD within the broader global Phase III obesity program in overweight and obesity, including key sub-populations.15,16,17,18,19,20 Survodutide is also being studied in two global Phase III clinical trials LIVERAGE and LIVERAGE-Cirrhosis investigating the efficacy and safety of survodutide in adults with MASH and fibrosis stages 2 or 3 and in those with compensated MASH cirrhosis (fibrosis stage 4).21,22 

Copyright 2026 GlobeNewswire, Inc.

HONG KONG SAR - Media OutReach Newswire - 5 June 2026 - A large high-level business delegation led by John Lee, Chief Executive of the Hong Kong Special Administrative Region (HKSAR), today (June 5) wrapped up its five-day visit to Kazakhstan and Uzbekistan respectively, achieving fruitful results of strengthening bilateral relations and deepening ties with Central Asia.

The delegation of over 70 business and institutional leaders from Hong Kong and the Chinese Mainland is the largest and most diverse overseas mission led by the current term of the HKSAR Government so far.

Speaking to the media in Uzbekistan yesterday (June 4), Mr Lee set out the three main objectives of the visit: further explore emerging markets and lay the foundation for long-term economic and trade development; strengthen government-to-government (G2G) relationships and promote closer bilateral co-operation; and build a "hub-to-hub" model of co-operation.

He said the visit had been successful, yielding achievements in eight areas, including:

Establishing high-level contacts and ties between the HKSAR Government and the Governments of Kazakhstan and Uzbekistan, and reaching consensus on co-operation in multiple areas;

A total of 96 co-operation agreements and memoranda of understanding (MoUs) were reached during the visit (61 with Kazakhstan, 35 with Uzbekistan), involving specific amounts exceeding US$1.65 billion in total;

The governments agreed to commence bilateral discussions on agreements in various areas;

Deepening project matching and research collaboration between Hong Kong and Central Asian region in areas including finance, innovation and technology (I&T), and aviation;

Demonstrating Hong Kong's effective role as a platform for going global and achieving substantial results, with Hong Kong and Mainland enterprises joining forces in tapping new markets and bringing synergistic advantages into full play;

Facilitating more convenient people-to-people exchanges by promoting direct flights, aviation and transport co-operation, and extensions to the mutual visa-free period;

Promoting exchanges in education, talent and culture to further deepen people-to-people bonds; and

Advancing a hub-to-hub co-operation model to open up broader room for co-operation between Hong Kong and the Central Asian region.

While in Tashkent (June 3-5), Mr Lee met with local leaders, government officials and business representatives to deepen co-operation between Hong Kong and Uzbekistan in areas including trade, investment, finance, I&T, and people-to-people exchanges.

Mr Lee held meetings with the President of Uzbekistan, Shavkat Miromonovich Mirziyoyev, his Advisor on Strategic Development, Sardor Umurzakov, the Prime Minister, Abdulla Nigmatovich Aripov, as well as the Deputy Prime Minister, Jamshid Khodjayev, to exchange views on furthering mutual co-operation.

Mr Lee highlighted that under the "one country, two systems" principle, Hong Kong enjoys both the China advantage and the global advantage. He said that Hong Kong would continue to play its roles as a "super connector" and a "super value-adder" to further deepen co-operation and exchanges with Uzbekistan on various fronts in line with Uzbekistan's goal of achieving high-quality development.

Earlier (June 3), Mr Lee met with the Minister of Foreign Affairs of Uzbekistan, Bakhtiyor Saidov, after which they jointly witnessed an exchange of notes between the two places on a mutual visa-free arrangement, which would allow a visa-free period of 30 days for visitors from both sides.

"Moreover, we are glad to have initialed the Air Services Agreement with Uzbekistan, and look forward to launching direct passenger flights between the two places soon," Mr Lee said, during a high-level business dinner (June 4). The Chief Executive pointed out that Hong Kong and Uzbekistan are important trade and investment gateways to their respective regions - the Asia-Pacific and Central Asia.

"It helps that we are all believers in the Belt and Road (B&R) Initiative, a modern expression of the ancient Silk Road spirit," Mr Lee said. "Today, China is Uzbekistan's largest trading partner, and the two countries work closely on major infrastructure and connectivity projects that are revitalising the Silk Road. Hong Kong is a pivotal player in the B&R Initiative, thanks to our world-class professional and financial services expertise."

The delegation also toured the IT Park Uzbekistan and the Center for Islamic Civilization before concluding its visit in Tashkent.

The issuer is solely responsible for the content of this announcement.

NEWARK, N.J., June 07, 2026 (GLOBE NEWSWIRE) -- Yuno, platform pasar prediksi yang sedang berkembang dan berfokus pada pembangunan infrastruktur global untuk trading berbasis peristiwa serta partisipasi sosial, hari ini menyampaikan info terbaru perusahaan yang menyoroti sejumlah pencapaian penting menjelang peluncuran, termasuk perluasan tim pemimpin, kemajuan pengembangan produk, strategi pasar internasional, dan investasi berkelanjutan dalam infrastruktur regulasi.

Info terbaru ini disampaikan di tengah percepatan pertumbuhan global pasar prediksi, kategori yang kian menarik minat trader ritel, perhatian institusi, pelaku aset digital, serta audiens mainstream yang mencari cara baru untuk menemukan informasi dan melakukan trading berbasis peristiwa.

Yuno sedang mengembangkan hal yang digambarkan manajemen sebagai ekosistem pasar prediksi generasi berikutnya, yang dirancang untuk menggabungkan kontrak berbasis tindakan peristiwa, partisipasi sosial, infrastruktur pasar berbasis kreator, serta pengalaman trading secara real time ke dalam satu platform yang dioptimalkan untuk ekspansi internasional.

Perusahaan meyakini bahwa pasar prediksi masih berada pada tahap awal adopsi global, sekalipun sektor ini telah mengalami pertumbuhan pesat selama beberapa tahun terakhir.

"Pasar prediksi sedang berevolusi dari produk internet yang sangat spesifik menjadi kategori keuangan baru," ujar Sigmund Holtz, Co-Founder dan CEO Yuno. "Kami percaya bahwa pengguna semakin mencari pengalaman yang memadukan partisipasi pasar, penemuan informasi, keterlibatan sosial, dan reputasi. Fokus kami adalah membangun infrastruktur yang mendukung perilaku-perilaku tersebut pada skala besar."

Memperkuat Kepemimpinan dengan Pengalaman Industri

Sebagai bagian dari persiapannya menuju peluncuran, Yuno telah memperluas kapabilitas kepemimpinan dan operasionalnya melalui penambahan personel senior dan penasihat yang berpengalaman di bidang aset digital, infrastruktur bursa, pasar prediksi, sistem pertumbuhan, dan operasional pasar.

Perusahaan baru-baru ini menambah sejumlah anggota tim senior dan pendiri dengan latar belakang dari berbagai organisasi, termasuk Binance, yang menghadirkan pengalaman operasional dari beberapa bisnis infrastruktur pasar terbesar dan paling cepat berkembang secara global.

Manajemen meyakini bahwa kombinasi keahlian di bidang bursa, likuiditas, produk, dan pertumbuhan ini memperkuat posisi Yuno untuk mempercepat eksekusi produk, sekaligus membangun sistem operasional yang dirancang untuk mendukung skala internasional.

Membangun Pasar Prediksi Dengan Prinsip Infrastruktur Trading

Pada dasarnya, Yuno dirancang sebagai platform infrastruktur pasar berbasis peristiwa yang memungkinkan pengguna memperoleh eksposur terhadap berbagai hasil di dunia nyata melalui mekanisme penetapan harga yang dinamis dan digerakkan oleh pasar.

Berbeda dengan sistem prediksi tradisional yang penetapan harganya ditentukan secara terpusat, arsitektur platform Yuno dikembangkan dengan berfokus pada mekanisme penemuan berbasis pasar yang dirancang untuk mendukung likuiditas yang lebih dalam, penyesuaian harga yang lebih cepat, serta partisipasi yang lebih luas di berbagai kategori pasar.

Antarmuka Yuno sedang dikembangkan berdasarkan prinsip yang mengutamakan trading, dengan menekankan pada:

* Harga pasar real time

* Infrastruktur buku order real time

* Pembuatan kontrak berbasis peristiwa

* Partisipasi pasar sosial

* Sistem peramalan komunitas

* Alat penemuan di pasar

* Mekanisme partisipasi berbasis reputasi

Manajemen meyakini bahwa pelaku pasar saat ini semakin mengharapkan infrastruktur yang bekerja lebih seperti sistem trading finansial, bukan seperti produk tradisional.

Mengembangkan Lapisan Sosial untuk Pasar Berbasis Peristiwa

Salah satu pembeda utama produk Yuno adalah rencana pengembangan lapisan infrastruktur sosialnya.

Platform ini sedang membangun fungsionalitas komunitas terintegrasi yang dirancang untuk memungkinkan pengguna mendiskusikan pasar, memublikasikan pandangan, membangun reputasi trading publik, dan berpartisipasi dalam sistem peramalan berbasis komunitas.

Yuno meyakini bahwa pasar berbasis peristiwa secara alami mendorong timbulnya percakapan, keyakinan, dan berbagi informasi sehingga perilaku tersebut seharusnya tertanam langsung dalam pengalaman platform.

Fungsionalitas sosial yang direncanakan dan saat ini sedang dikembangkan mencakup:

* Feed sosial seputar pasar aktif

* Sistem reputasi trader terverifikasi

* Alat partisipasi komunitas

* Infrastruktur untuk membangun audiens

* Sistem partisipasi pasar buatan pengguna

* Fitur keterlibatan komunitas

"Masa depan pasar prediksi tidak hanya bertumpu pada partisipasi pasif," tambah Holtz. "Pengguna semakin menginginkan transparansi terkait pelaku pasar, interaksi komunitas yang lebih kuat, serta cara untuk membangun kredibilitas seiring waktu. Kami meyakini bahwa sistem reputasi menjadi semakin penting seiring meningkatnya skala pasar."

Strategi Ekspansi Internasional yang Dibangun Berdasarkan Infrastruktur Regulasi

Strategi pertumbuhan internasional Yuno dirancang secara terarah dengan mengacu pada ekspansi pasar bertahap dan penyelarasan regulasi.

Strategi internasional perusahaan yang dibangun untuk menciptakan infrastruktur pasar yang dapat diakses secara global, guna memungkinkan partisipasi di berbagai yurisdiksi dengan adopsi aset digital yang terus meningkat, keterlibatan ritel yang semakin luas, serta kerangka regulasi yang terus berkembang untuk mendukung pengembangan pasar jangka panjang.

Platform ini menerapkan infrastruktur yang dirancang untuk mendukung:

? Proses AML dan KYC

? Sistem pemantauan transaksi

? Pemeriksaan terhadap daftar sanksi

? Alur kerja kepatuhan

? Kontrol integritas pasar

Peluang ekspansi tambahan di pasar MENA dan Asia Pasifik masih dalam tahap evaluasi saat perusahaan menilai kerangka perizinan serta kesiapan pasar.

Yuno berencana membatasi akses di yurisdiksi tempat platformnya belum memperoleh izin yang diperlukan. Untuk Amerika Serikat, tujuan jangka panjang Yuno mencakup upaya menempuh jalur regulasi yang sesuai agar dapat memasuki pasar tersebut dengan taat regulasi.

Menargetkan Kategori Global yang Berkembang Pesat

Pasar prediksi telah muncul sebagai salah satu segmen dengan pertumbuhan tercepat dalam keuangan digital dan trading berbasis peristiwa.

Manajemen meyakini bahwa pertumbuhan kategori ini terus didukung oleh sejumlah faktor struktural, termasuk:

* Meningkatnya adopsi stablecoin

* Perluasan infrastruktur aset digital

* Meningkatnya partisipasi ritel di pasar alternatif

* Permintaan terhadap pasar informasi real time

* Meningkatnya pemahaman tentang produk trading berbasis peristiwa

Yuno meyakini bahwa dinamika tersebut membuka peluang bagi pelaku pasar baru yang mampu memadukan likuiditas, pengalaman produk, infrastruktur regulasi, dan partisipasi komunitas dalam satu ekosistem terpadu.

"Bisnis ini pada akhirnya merupakan bisnis yang berlandaskan kepercayaan dan infrastruktur," ujar Holtz. "Likuiditas itu penting. Penyelesaian pasar yang adil itu penting. Pengalaman pengguna itu penting. Kami membangun dengan mengedepankan prioritas-prioritas tersebut."

Menatap ke Depan

Dengan berlanjutnya pengembangan, manajemen tetap berfokus pada penyelesaian target penting dalam pengembangan produk, perluasan kemitraan strategis, penguatan infrastruktur, dan persiapan memasuki pasar secara bertahap. Perusahaan menargetkan volume bulanan rata-rata selama 12 bulan ke depan dari sekitar 200.000 pengguna aktif dan total volume sebesar US$4 miliar pada akhir tahun 2027, tergantung waktu peluncuran platform.

Perusahaan berencana menyampaikan info terbaru tambahan terkait pencapaian peluncuran, kemitraan, dan perkembangan produk dalam pengumuman mendatang.

Pernyataan Berwawasan ke Depan

Siaran pers ini memuat pernyataan berwawasan ke depan terkait rencana masa depan, peluang pasar, pengembangan produk, dan inisiatif ekspansi. Hasil aktual dapat berbeda secara signifikan dari ekspektasi karena faktor regulasi, pasar, operasional, serta persaingan.

Trading di pasar prediksi melibatkan risiko. Performa investasi pada masa lalu tidak menjamin hasil pada masa mendatang.

Tentang Yuno

Yuno sedang membangun platform pasar prediksi global yang dirancang untuk memadukan trading berbasis peristiwa, infrastruktur sosial, dan infrastruktur pasar ke dalam satu pengalaman terpadu bagi pengguna internasional. Perusahaan berfokus mengembangkan sistem yang skalabel, yang memungkinkan pengguna berpartisipasi dalam pasar berbasis peristiwa yang transparan dan digerakkan oleh komunitas.

Kontak: press@yuno.trade

Copyright 2026 GlobeNewswire, Inc.

NEWARK, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Yuno, an emerging prediction markets platform focused on building global infrastructure for event-based trading and social participation, today provided a corporate update highlighting key milestones achieved ahead of launch, including leadership expansion, product development progress, international market strategy, and continued investment in regulatory infrastructure.

The update comes amid accelerating global growth across prediction markets, a category increasingly attracting retail traders, institutional attention, digital asset participants, and mainstream audiences seeking new forms of information discovery and event-driven trading.

Yuno is developing what management describes as a next-generation prediction market ecosystem designed to combine event contracts, social participation, creator-driven market infrastructure, and real-time trading experiences into a single platform optimized for international expansion.

The company believes prediction markets remain in the early stages of global adoption despite rapid growth across the sector over the past several years.

"Prediction markets are evolving from niche internet products into a new financial category," said Sigmund Holtz, Co-Founder and CEO of Yuno. "We believe users increasingly want experiences that combine market participation, information discovery, social engagement, and reputation. Our focus is building infrastructure that supports those behaviors at scale."

Strengthening Leadership With Industry Experience

As part of its preparation for launch, Yuno has expanded its leadership and operational capabilities through the addition of senior personnel and advisors with experience across digital assets, exchange infrastructure, prediction markets, growth systems, and market operations.

The company has recently added several senior team members and founders with backgrounds spanning organizations including Binance, bringing operational experience from some of the largest and fastest-growing market infrastructure businesses globally.

Management believes this combination of exchange, liquidity, product, and growth expertise positions Yuno to accelerate product execution while building operational systems designed to support international scale.

Building Prediction Markets With Trading Infrastructure Principles

At its core, Yuno is being designed as an event-based market infrastructure platform where users can gain exposure to real-world outcomes through dynamic, market-driven pricing.

Unlike traditional prediction systems where pricing is centrally determined, Yuno's platform architecture is being developed around market-based discovery mechanisms intended to support deeper liquidity, faster pricing adjustments, and broader participation across multiple market categories.

The company's interface is being built with trading-first principles, emphasizing:

? Real-time market pricing

? Live order book infrastructure

? Event-driven contract creation

? Social market participation

? Community forecasting systems

? Market discovery tools

? Reputation-driven participation mechanisms

Management believes current market participants increasingly expect infrastructure that behaves more like financial trading systems and less like traditional products.

Developing A Social Layer For Event Markets

One of Yuno's primary product differentiators is its planned social infrastructure layer.

The platform is building integrated community functionality intended to allow users to discuss markets, publish views, establish public trading reputations, and participate in community-driven forecasting systems.

Yuno believes event markets naturally generate conversation, conviction, and information sharing and that these behaviors should exist natively inside the platform experience.

Planned social functionality currently under development includes:

? Social feeds around active markets

? Verified trader reputation systems

? Community participation tools

? Audience-building infrastructure

? User-generated market participation systems

? Community engagement functionality

"The future of prediction markets is not just passive participation," Holtz added. "Users increasingly want transparency around market participants, stronger community interaction, and ways to build credibility over time. We believe reputation systems become increasingly important as markets scale."

International Expansion Strategy Built Around Regulatory Infrastructure

Yuno's international growth strategy is intentionally structured around phased market expansion and regulatory alignment.

The company's international strategy is built around creating globally accessible market infrastructure, enabling participation across jurisdictions where growing digital asset adoption, expanding retail engagement, and evolving regulatory frameworks support long-term market development.

The platform is implementing infrastructure intended to support:

* AML and KYC processes

* Transaction monitoring systems

* Sanctions screening

* Compliance workflows

* Market integrity controls

Additional expansion opportunities across MENA and Asia-Pacific markets remain under evaluation as the company assesses licensing frameworks and market readiness.

Yuno intends to restrict access in jurisdictions where the platform does not yet hold required permissions. For the United States, Yuno's long-term objective includes pursuing appropriate regulatory pathways to enter the market compliantly.

Targeting A Rapidly Expanding Global Category

Prediction markets have emerged as one of the fastest-growing segments within digital finance and event-based trading.

Management believes several structural tailwinds continue supporting category growth including:

? Rising stablecoin adoption

? Expansion of digital asset infrastructure

? Increased retail participation in alternative markets

? Demand for real-time information markets

? Growing familiarity with event-based trading products

Yuno believes these dynamics create an opportunity for new entrants capable of combining liquidity, product experience, regulatory infrastructure, and community participation into unified ecosystems.

"This is ultimately a trust and infrastructure business," Holtz said. "Liquidity matters. Fair market resolution matters. User experience matters. We are building with those priorities first."

Looking Ahead

As development continues, management remains focused on completing product milestones, expanding strategic partnerships, strengthening infrastructure, and preparing for phased market entry. The company is targeting average monthly volume over the next 12 months of approximately 200,000 active users and US$4 billion in total volume by the end of 2027, subject to platform launch timing.

The company expects additional updates relating to launch milestones, partnerships, and product developments in future announcements.

Forward-Looking Statements

This release contains forward-looking statements regarding future plans, market opportunities, product development, and expansion initiatives. Actual outcomes may differ materially from expectations due to regulatory, market, operational, and competitive factors.

Trading on prediction markets involves risk. Past performance does not guarantee future results.

About Yuno

Yuno is building a global prediction markets platform designed to combine event-based trading, social infrastructure, and market infrastructure into a unified experience for international users. The company is focused on developing scalable systems that enable users to participate in transparent, community-driven event markets.

Contact: press@yuno.trade

Copyright 2026 GlobeNewswire, Inc.

*Teva Presents New Data on AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

*New real-world survey data reveal the daily impact of Huntington's disease (HD) chorea, with over 68% of patients reporting interference with social life or emotional wellbeing1 and up to 83% of caregivers noting impact on their own daily lives.2

*Following treatment with AUSTEDO or AUSTEDO XR, most patients (60-71%) reported improvement across multiple quality of life domains as a result of their improved movements.1 As a result of the patient's reduced chorea impact, most caregivers reported less impact to their daily lives.2

*These real-world findings reinforce Teva's commitment to advancing innovative treatment options that improve the lives of individuals living with HD chorea and their caregivers.

PARSIPPANY, N.J. and TEL AVIV, Israel, June 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the first and only real-world, decentralized study evaluating the patient- and caregiver-reported quality of life impacts of Huntington's disease (HD) chorea3 and the effect of AUSTEDO? or AUSTEDO XR? on symptom management. The findings demonstrate that treating chorea with AUSTEDO or AUSTEDO XR led to symptom improvement and, as a result, showed improvements across multiple quality of life measures.1,2 The data were presented at the Advanced Therapeutics in Movement & Related Disorders? Congress, held June 4 ? 8, 2026, in Washington, DC.

"What we are seeing reinforced from these real-world data is how deeply Huntington's disease chorea affects patients ? physically, emotionally and in their ability to function day-to-day ? and the strain it can place on their care partners," said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. "That's why our patient-centric approach is fundamental to our work at Teva, and why we are proud to see AUSTEDO and AUSTEDO XR delivering such meaningful improvement for patients and making a real difference in the lives of those impacted."

Self-reported HD chorea patient participants (≥18 years) in the United States completed a non-interventional, online survey through the myHDstory? platform, which included questions regarding chorea impact on quality of life, severity, current treatment and self-defined goals for management. Participants taking AUSTEDO or AUSTEDO XR completed additional questions evaluating perceived changes in burden since treatment initiation, including the Patient Global Impression of Change (PGIC) scale. Caregivers (≥18 years) of individuals with HD chorea also completed an online survey, reporting on how their care recipient's chorea affected their own daily functioning across multiple quality of life domains.

Prior to treatment survey findings revealed:

Patients reported self-defined aspirational goals that they would like to improve with HD chorea treatment focused on their daily activities and social life. Caregivers also reported goals focused on their own wellbeing.

Across the real-world survey population, patients reported HD chorea often interfered with social life (71-84%), emotional wellbeing (68-77%), daily activities (70-78%) and vocational/recreational life (67-82%).1 Caregivers also reported substantial impact across their own social functioning (73?84%), emotional wellbeing (71?84%), daily activities (81?83%) and vocational/recreational life (76-83%) due to their caregiving responsibilities.2

As a result of reduced HD chorea movements in patients treated with AUSTEDO or AUSTEDO XR, the survey findings revealed:

74% of patients reported improvements in their chorea movements since initiating treatment, measured by the PGIC scale.1

As a result of movement reduction, over 85% of surveyed patients reported improvements in goals related to daily activities, such as dressing, walking and eating, and goals related to their social lives, such as going out with friends and family.1

77% of caregivers of patients reported improvements in goals related to their social life, such as going out on their own and emotional wellbeing, including reduced guilt, stress and emotional burden.2

"Huntington's disease chorea extends beyond its physical symptoms, disrupting patients' emotional wellbeing, social functioning and sense of self, while also placing immense strain on caregivers," said Daniel Claassen, MD, MS, Professor of Neurology at Vanderbilt University Medical Center, principal investigator of the study and CEO, Huntington's Study Group. "These real-world findings demonstrate the importance of effective chorea management to aid in preserving independence longer and alleviating those impacts for both patients and caregivers."

The study presented, executed in collaboration with the Huntington Study Group, is the only real-world study assessing the impact of HD chorea on patients' and caregivers' quality of life to date.3

About Chorea Associated with Huntington's Disease (HD)

Huntington's disease (HD) is a fatal neurodegenerative disease characterized by uncoordinated and uncontrollable movements, cognitive deterioration and behavioral and/or psychological problems. Chorea ? involuntary, random and sudden, twisting and/or writhing movements ? is one of the most striking physical manifestations of Huntington's disease and occurs in approximately 90% of patients. Chorea can have a significant impact on daily activities and progressively limit peoples' lives.4,5

About AUSTEDO XR Extended-Release Tablets and AUSTEDO Tablets

AUSTEDO XR and AUSTEDO are the first vesicular monoamine transporter 2 (VMAT2) inhibitors approved by the U.S. Food and Drug Administration in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington's disease. Safety and effectiveness in pediatric patients have not been established. AUSTEDO XR is the once-daily formulation of AUSTEDO.

INDICATIONS AND USAGE

AUSTEDO XR (deutetrabenazine) extended-release tablets and AUSTEDO (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington's disease and for the treatment of tardive dyskinesia.

IMPORTANT SAFETY INFORMATION 

Depression and Suicidality in Patients with Huntington's Disease: AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidality and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation. AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression. 

Contraindications: AUSTEDO XR and AUSTEDO are contraindicated in patients with Huntington's disease who are suicidal, or have untreated or inadequately treated depression. AUSTEDO XR and AUSTEDO are also contraindicated in: patients with hepatic impairment; patients taking reserpine or within 20 days of discontinuing reserpine; patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing MAOI therapy; and patients taking tetrabenazine or valbenazine.   

Clinical Worsening and Adverse Events in Patients with Huntington's Disease: AUSTEDO XR and AUSTEDO may cause a worsening in mood, cognition, rigidity, and functional capacity. Prescribers should periodically re-evaluate the need for AUSTEDO XR or AUSTEDO in their patients by assessing the effect on chorea and possible adverse effects. 

QTc Prolongation: AUSTEDO XR and AUSTEDO may prolong the QT interval, but the degree of QT prolongation is not clinically significant when AUSTEDO XR or AUSTEDO is administered within the recommended dosage range. AUSTEDO XR and AUSTEDO should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.  

Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex reported in association with drugs that reduce dopaminergic transmission, has been observed in patients receiving tetrabenazine. The risk may be increased by concomitant use of dopamine antagonists or antipsychotics. The management of NMS should include immediate discontinuation of AUSTEDO XR and AUSTEDO; intensive symptomatic treatment and medical monitoring; and treatment of any concomitant serious medical problems.   

Akathisia, Agitation, and Restlessness: AUSTEDO XR and AUSTEDO may increase the risk of akathisia, agitation, and restlessness. The risk of akathisia may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops akathisia, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy. 

Parkinsonism: AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntington's disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. The risk of parkinsonism may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops parkinsonism, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy. 

Sedation and Somnolence: Sedation is a common dose-limiting adverse reaction of AUSTEDO XR and AUSTEDO. Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, until they are on a maintenance dose of AUSTEDO XR or AUSTEDO and know how the drug affects them. Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence. 

Hyperprolactinemia: Tetrabenazine elevates serum prolactin concentrations in humans. If there is a clinical suspicion of symptomatic hyperprolactinemia, appropriate laboratory testing should be done and consideration should be given to discontinuation of AUSTEDO XR and AUSTEDO.   

Binding to Melanin-Containing Tissues: Deutetrabenazine or its metabolites bind to melanin-containing tissues and could accumulate in these tissues over time. Prescribers should be aware of the possibility of long-term ophthalmologic effects. 

Common Adverse Reactions: The most common adverse reactions for AUSTEDO (>8% and greater than placebo) in a controlled clinical study in patients with Huntington's disease were somnolence, diarrhea, dry mouth, and fatigue. The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia.  Adverse reactions with AUSTEDO XR extended-release tablets are expected to be similar to AUSTEDO tablets. 

Please see accompanying full Prescribing Information, including Boxed Warning. 

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Teva Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize AUSTEDO and AUSTEDO XR for the treatment of chorea associated with Huntington's disease; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors" and "Forward-Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

References:

Claassen D, Dalrymple WA, Finkbeiner S, Klakotskaia D, Konings M, & Gandhi P, (2026, June 4-8). Patient-reported burden of Huntington disease chorea and effect of deutetrabenazine on symptom management and quality of life: Results from a real-world, decentralized study [Poster presentation]. Advanced Therapeutics in Movement & Related Disorders? Congress, Washington, DC, United States.

Anderson KE, Moore HP, Finkbeiner S, Klakotskaia D, Konings M, & Gandhi P, (2026, June 4?8). A real-world, decentralized study of caregiver-reported burden of Huntington disease chorea and effect of deutetrabenazine on symptom management and quality of life [Poster presentation]. Advanced Therapeutics in Movement & Related Disorders? Congress, Washington, DC, United States.

Data on file. Parsippany, NJ: Teva Neuroscience, Inc.

Huntington's Disease. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/health-information/disorders/huntingtons-disease#toc-what-is-huntington-s-disease-.

Thorley EM, Iyer RG, Wicks P, Curran C, Gandhi SK, Abler V, Anderson KE, Carlozzi NE. Understanding How Chorea Affects Health-Related Quality of Life in Huntington Disease: An Online Survey of Patients and Caregivers in the United States. Patient. 2018;11(5):547-559. doi: 10.1007/s40271-018-0312-x.

Teva Media

Inquiries TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor

Relations

Inquiries TevaIR@Tevapharm.com

Copyright 2026 GlobeNewswire, Inc.

*Teva Presents New Data on AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

*New real-world survey data reveal the daily impact of Huntington's disease (HD) chorea, with over 68% of patients reporting interference with social life or emotional wellbeing1 and up to 83% of caregivers noting impact on their own daily lives.2

*Following treatment with AUSTEDO or AUSTEDO XR, most patients (60-71%) reported improvement across multiple quality of life domains as a result of their improved movements.1 As a result of the patient's reduced chorea impact, most caregivers reported less impact to their daily lives.2

*These real-world findings reinforce Teva's commitment to advancing innovative treatment options that improve the lives of individuals living with HD chorea and their caregivers.

PARSIPPANY, N.J. and TEL AVIV, Israel, June 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the first and only real-world, decentralized study evaluating the patient- and caregiver-reported quality of life impacts of Huntington's disease (HD) chorea3 and the effect of AUSTEDO? or AUSTEDO XR? on symptom management. The findings demonstrate that treating chorea with AUSTEDO or AUSTEDO XR led to symptom improvement and, as a result, showed improvements across multiple quality of life measures.1,2 The data were presented at the Advanced Therapeutics in Movement & Related Disorders? Congress, held June 4 ? 8, 2026, in Washington, DC.

"What we are seeing reinforced from these real-world data is how deeply Huntington's disease chorea affects patients ? physically, emotionally and in their ability to function day-to-day ? and the strain it can place on their care partners," said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. "That's why our patient-centric approach is fundamental to our work at Teva, and why we are proud to see AUSTEDO and AUSTEDO XR delivering such meaningful improvement for patients and making a real difference in the lives of those impacted."

Self-reported HD chorea patient participants (≥18 years) in the United States completed a non-interventional, online survey through the myHDstory? platform, which included questions regarding chorea impact on quality of life, severity, current treatment and self-defined goals for management. Participants taking AUSTEDO or AUSTEDO XR completed additional questions evaluating perceived changes in burden since treatment initiation, including the Patient Global Impression of Change (PGIC) scale. Caregivers (≥18 years) of individuals with HD chorea also completed an online survey, reporting on how their care recipient's chorea affected their own daily functioning across multiple quality of life domains.

Prior to treatment survey findings revealed:

Patients reported self-defined aspirational goals that they would like to improve with HD chorea treatment focused on their daily activities and social life. Caregivers also reported goals focused on their own wellbeing.

Across the real-world survey population, patients reported HD chorea often interfered with social life (71-84%), emotional wellbeing (68-77%), daily activities (70-78%) and vocational/recreational life (67-82%).1 Caregivers also reported substantial impact across their own social functioning (73?84%), emotional wellbeing (71?84%), daily activities (81?83%) and vocational/recreational life (76-83%) due to their caregiving responsibilities.2

As a result of reduced HD chorea movements in patients treated with AUSTEDO or AUSTEDO XR, the survey findings revealed:

74% of patients reported improvements in their chorea movements since initiating treatment, measured by the PGIC scale.1

As a result of movement reduction, over 85% of surveyed patients reported improvements in goals related to daily activities, such as dressing, walking and eating, and goals related to their social lives, such as going out with friends and family.1

77% of caregivers of patients reported improvements in goals related to their social life, such as going out on their own and emotional wellbeing, including reduced guilt, stress and emotional burden.2

"Huntington's disease chorea extends beyond its physical symptoms, disrupting patients' emotional wellbeing, social functioning and sense of self, while also placing immense strain on caregivers," said Daniel Claassen, MD, MS, Professor of Neurology at Vanderbilt University Medical Center, principal investigator of the study and CEO, Huntington's Study Group. "These real-world findings demonstrate the importance of effective chorea management to aid in preserving independence longer and alleviating those impacts for both patients and caregivers."

The study presented, executed in collaboration with the Huntington Study Group, is the only real-world study assessing the impact of HD chorea on patients' and caregivers' quality of life to date.3

About Chorea Associated with Huntington's Disease (HD)

Huntington's disease (HD) is a fatal neurodegenerative disease characterized by uncoordinated and uncontrollable movements, cognitive deterioration and behavioral and/or psychological problems. Chorea ? involuntary, random and sudden, twisting and/or writhing movements ? is one of the most striking physical manifestations of Huntington's disease and occurs in approximately 90% of patients. Chorea can have a significant impact on daily activities and progressively limit peoples' lives.4,5

About AUSTEDO XR Extended-Release Tablets and AUSTEDO Tablets

AUSTEDO XR and AUSTEDO are the first vesicular monoamine transporter 2 (VMAT2) inhibitors approved by the U.S. Food and Drug Administration in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington's disease. Safety and effectiveness in pediatric patients have not been established. AUSTEDO XR is the once-daily formulation of AUSTEDO.

INDICATIONS AND USAGE

AUSTEDO XR (deutetrabenazine) extended-release tablets and AUSTEDO (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington's disease and for the treatment of tardive dyskinesia.

IMPORTANT SAFETY INFORMATION 

Depression and Suicidality in Patients with Huntington's Disease: AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidality and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation. AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression. 

Contraindications: AUSTEDO XR and AUSTEDO are contraindicated in patients with Huntington's disease who are suicidal, or have untreated or inadequately treated depression. AUSTEDO XR and AUSTEDO are also contraindicated in: patients with hepatic impairment; patients taking reserpine or within 20 days of discontinuing reserpine; patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing MAOI therapy; and patients taking tetrabenazine or valbenazine.   

Clinical Worsening and Adverse Events in Patients with Huntington's Disease: AUSTEDO XR and AUSTEDO may cause a worsening in mood, cognition, rigidity, and functional capacity. Prescribers should periodically re-evaluate the need for AUSTEDO XR or AUSTEDO in their patients by assessing the effect on chorea and possible adverse effects. 

QTc Prolongation: AUSTEDO XR and AUSTEDO may prolong the QT interval, but the degree of QT prolongation is not clinically significant when AUSTEDO XR or AUSTEDO is administered within the recommended dosage range. AUSTEDO XR and AUSTEDO should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.  

Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex reported in association with drugs that reduce dopaminergic transmission, has been observed in patients receiving tetrabenazine. The risk may be increased by concomitant use of dopamine antagonists or antipsychotics. The management of NMS should include immediate discontinuation of AUSTEDO XR and AUSTEDO; intensive symptomatic treatment and medical monitoring; and treatment of any concomitant serious medical problems.   

Akathisia, Agitation, and Restlessness: AUSTEDO XR and AUSTEDO may increase the risk of akathisia, agitation, and restlessness. The risk of akathisia may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops akathisia, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy. 

Parkinsonism: AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntington's disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. The risk of parkinsonism may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops parkinsonism, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy. 

Sedation and Somnolence: Sedation is a common dose-limiting adverse reaction of AUSTEDO XR and AUSTEDO. Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, until they are on a maintenance dose of AUSTEDO XR or AUSTEDO and know how the drug affects them. Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence. 

Hyperprolactinemia: Tetrabenazine elevates serum prolactin concentrations in humans. If there is a clinical suspicion of symptomatic hyperprolactinemia, appropriate laboratory testing should be done and consideration should be given to discontinuation of AUSTEDO XR and AUSTEDO.   

Binding to Melanin-Containing Tissues: Deutetrabenazine or its metabolites bind to melanin-containing tissues and could accumulate in these tissues over time. Prescribers should be aware of the possibility of long-term ophthalmologic effects. 

Common Adverse Reactions: The most common adverse reactions for AUSTEDO (>8% and greater than placebo) in a controlled clinical study in patients with Huntington's disease were somnolence, diarrhea, dry mouth, and fatigue. The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia.  Adverse reactions with AUSTEDO XR extended-release tablets are expected to be similar to AUSTEDO tablets. 

Please see accompanying full Prescribing Information, including Boxed Warning. 

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Teva Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize AUSTEDO and AUSTEDO XR for the treatment of chorea associated with Huntington's disease; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors" and "Forward-Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

References:

Claassen D, Dalrymple WA, Finkbeiner S, Klakotskaia D, Konings M, & Gandhi P, (2026, June 4-8). Patient-reported burden of Huntington disease chorea and effect of deutetrabenazine on symptom management and quality of life: Results from a real-world, decentralized study [Poster presentation]. Advanced Therapeutics in Movement & Related Disorders? Congress, Washington, DC, United States.

Anderson KE, Moore HP, Finkbeiner S, Klakotskaia D, Konings M, & Gandhi P, (2026, June 4?8). A real-world, decentralized study of caregiver-reported burden of Huntington disease chorea and effect of deutetrabenazine on symptom management and quality of life [Poster presentation]. Advanced Therapeutics in Movement & Related Disorders? Congress, Washington, DC, United States.

Data on file. Parsippany, NJ: Teva Neuroscience, Inc.

Huntington's Disease. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/health-information/disorders/huntingtons-disease#toc-what-is-huntington-s-disease-.

Thorley EM, Iyer RG, Wicks P, Curran C, Gandhi SK, Abler V, Anderson KE, Carlozzi NE. Understanding How Chorea Affects Health-Related Quality of Life in Huntington Disease: An Online Survey of Patients and Caregivers in the United States. Patient. 2018;11(5):547-559. doi: 10.1007/s40271-018-0312-x.

Teva Media

Inquiries TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor

Relations

Inquiries TevaIR@Tevapharm.com

Copyright 2026 GlobeNewswire, Inc.

*Teva Presents New Data on AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

*New real-world survey data reveal the daily impact of Huntington's disease (HD) chorea, with over 68% of patients reporting interference with social life or emotional wellbeing1 and up to 83% of caregivers noting impact on their own daily lives.2

*Following treatment with AUSTEDO or AUSTEDO XR, most patients (60-71%) reported improvement across multiple quality of life domains as a result of their improved movements.1 As a result of the patient's reduced chorea impact, most caregivers reported less impact to their daily lives.2

*These real-world findings reinforce Teva's commitment to advancing innovative treatment options that improve the lives of individuals living with HD chorea and their caregivers.

PARSIPPANY, N.J. and TEL AVIV, Israel, June 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the first and only real-world, decentralized study evaluating the patient- and caregiver-reported quality of life impacts of Huntington's disease (HD) chorea3 and the effect of AUSTEDO? or AUSTEDO XR? on symptom management. The findings demonstrate that treating chorea with AUSTEDO or AUSTEDO XR led to symptom improvement and, as a result, showed improvements across multiple quality of life measures.1,2 The data were presented at the Advanced Therapeutics in Movement & Related Disorders? Congress, held June 4 ? 8, 2026, in Washington, DC.

"What we are seeing reinforced from these real-world data is how deeply Huntington's disease chorea affects patients ? physically, emotionally and in their ability to function day-to-day ? and the strain it can place on their care partners," said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. "That's why our patient-centric approach is fundamental to our work at Teva, and why we are proud to see AUSTEDO and AUSTEDO XR delivering such meaningful improvement for patients and making a real difference in the lives of those impacted."

Self-reported HD chorea patient participants (≥18 years) in the United States completed a non-interventional, online survey through the myHDstory? platform, which included questions regarding chorea impact on quality of life, severity, current treatment and self-defined goals for management. Participants taking AUSTEDO or AUSTEDO XR completed additional questions evaluating perceived changes in burden since treatment initiation, including the Patient Global Impression of Change (PGIC) scale. Caregivers (≥18 years) of individuals with HD chorea also completed an online survey, reporting on how their care recipient's chorea affected their own daily functioning across multiple quality of life domains.

Prior to treatment survey findings revealed:

Patients reported self-defined aspirational goals that they would like to improve with HD chorea treatment focused on their daily activities and social life. Caregivers also reported goals focused on their own wellbeing.

Across the real-world survey population, patients reported HD chorea often interfered with social life (71-84%), emotional wellbeing (68-77%), daily activities (70-78%) and vocational/recreational life (67-82%).1 Caregivers also reported substantial impact across their own social functioning (73?84%), emotional wellbeing (71?84%), daily activities (81?83%) and vocational/recreational life (76-83%) due to their caregiving responsibilities.2

As a result of reduced HD chorea movements in patients treated with AUSTEDO or AUSTEDO XR, the survey findings revealed:

74% of patients reported improvements in their chorea movements since initiating treatment, measured by the PGIC scale.1

As a result of movement reduction, over 85% of surveyed patients reported improvements in goals related to daily activities, such as dressing, walking and eating, and goals related to their social lives, such as going out with friends and family.1

77% of caregivers of patients reported improvements in goals related to their social life, such as going out on their own and emotional wellbeing, including reduced guilt, stress and emotional burden.2

"Huntington's disease chorea extends beyond its physical symptoms, disrupting patients' emotional wellbeing, social functioning and sense of self, while also placing immense strain on caregivers," said Daniel Claassen, MD, MS, Professor of Neurology at Vanderbilt University Medical Center, principal investigator of the study and CEO, Huntington's Study Group. "These real-world findings demonstrate the importance of effective chorea management to aid in preserving independence longer and alleviating those impacts for both patients and caregivers."

The study presented, executed in collaboration with the Huntington Study Group, is the only real-world study assessing the impact of HD chorea on patients' and caregivers' quality of life to date.3

About Chorea Associated with Huntington's Disease (HD)

Huntington's disease (HD) is a fatal neurodegenerative disease characterized by uncoordinated and uncontrollable movements, cognitive deterioration and behavioral and/or psychological problems. Chorea ? involuntary, random and sudden, twisting and/or writhing movements ? is one of the most striking physical manifestations of Huntington's disease and occurs in approximately 90% of patients. Chorea can have a significant impact on daily activities and progressively limit peoples' lives.4,5

About AUSTEDO XR Extended-Release Tablets and AUSTEDO Tablets

AUSTEDO XR and AUSTEDO are the first vesicular monoamine transporter 2 (VMAT2) inhibitors approved by the U.S. Food and Drug Administration in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington's disease. Safety and effectiveness in pediatric patients have not been established. AUSTEDO XR is the once-daily formulation of AUSTEDO.

INDICATIONS AND USAGE

AUSTEDO XR (deutetrabenazine) extended-release tablets and AUSTEDO (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington's disease and for the treatment of tardive dyskinesia.

IMPORTANT SAFETY INFORMATION 

Depression and Suicidality in Patients with Huntington's Disease: AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidality and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation. AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression. 

Contraindications: AUSTEDO XR and AUSTEDO are contraindicated in patients with Huntington's disease who are suicidal, or have untreated or inadequately treated depression. AUSTEDO XR and AUSTEDO are also contraindicated in: patients with hepatic impairment; patients taking reserpine or within 20 days of discontinuing reserpine; patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing MAOI therapy; and patients taking tetrabenazine or valbenazine.   

Clinical Worsening and Adverse Events in Patients with Huntington's Disease: AUSTEDO XR and AUSTEDO may cause a worsening in mood, cognition, rigidity, and functional capacity. Prescribers should periodically re-evaluate the need for AUSTEDO XR or AUSTEDO in their patients by assessing the effect on chorea and possible adverse effects. 

QTc Prolongation: AUSTEDO XR and AUSTEDO may prolong the QT interval, but the degree of QT prolongation is not clinically significant when AUSTEDO XR or AUSTEDO is administered within the recommended dosage range. AUSTEDO XR and AUSTEDO should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.  

Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex reported in association with drugs that reduce dopaminergic transmission, has been observed in patients receiving tetrabenazine. The risk may be increased by concomitant use of dopamine antagonists or antipsychotics. The management of NMS should include immediate discontinuation of AUSTEDO XR and AUSTEDO; intensive symptomatic treatment and medical monitoring; and treatment of any concomitant serious medical problems.   

Akathisia, Agitation, and Restlessness: AUSTEDO XR and AUSTEDO may increase the risk of akathisia, agitation, and restlessness. The risk of akathisia may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops akathisia, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy. 

Parkinsonism: AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntington's disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. The risk of parkinsonism may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops parkinsonism, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy. 

Sedation and Somnolence: Sedation is a common dose-limiting adverse reaction of AUSTEDO XR and AUSTEDO. Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, until they are on a maintenance dose of AUSTEDO XR or AUSTEDO and know how the drug affects them. Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence. 

Hyperprolactinemia: Tetrabenazine elevates serum prolactin concentrations in humans. If there is a clinical suspicion of symptomatic hyperprolactinemia, appropriate laboratory testing should be done and consideration should be given to discontinuation of AUSTEDO XR and AUSTEDO.   

Binding to Melanin-Containing Tissues: Deutetrabenazine or its metabolites bind to melanin-containing tissues and could accumulate in these tissues over time. Prescribers should be aware of the possibility of long-term ophthalmologic effects. 

Common Adverse Reactions: The most common adverse reactions for AUSTEDO (>8% and greater than placebo) in a controlled clinical study in patients with Huntington's disease were somnolence, diarrhea, dry mouth, and fatigue. The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia.  Adverse reactions with AUSTEDO XR extended-release tablets are expected to be similar to AUSTEDO tablets. 

Please see accompanying full Prescribing Information, including Boxed Warning. 

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Teva Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize AUSTEDO and AUSTEDO XR for the treatment of chorea associated with Huntington's disease; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors" and "Forward-Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

References:

Claassen D, Dalrymple WA, Finkbeiner S, Klakotskaia D, Konings M, & Gandhi P, (2026, June 4-8). Patient-reported burden of Huntington disease chorea and effect of deutetrabenazine on symptom management and quality of life: Results from a real-world, decentralized study [Poster presentation]. Advanced Therapeutics in Movement & Related Disorders? Congress, Washington, DC, United States.

Anderson KE, Moore HP, Finkbeiner S, Klakotskaia D, Konings M, & Gandhi P, (2026, June 4?8). A real-world, decentralized study of caregiver-reported burden of Huntington disease chorea and effect of deutetrabenazine on symptom management and quality of life [Poster presentation]. Advanced Therapeutics in Movement & Related Disorders? Congress, Washington, DC, United States.

Data on file. Parsippany, NJ: Teva Neuroscience, Inc.

Huntington's Disease. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/health-information/disorders/huntingtons-disease#toc-what-is-huntington-s-disease-.

Thorley EM, Iyer RG, Wicks P, Curran C, Gandhi SK, Abler V, Anderson KE, Carlozzi NE. Understanding How Chorea Affects Health-Related Quality of Life in Huntington Disease: An Online Survey of Patients and Caregivers in the United States. Patient. 2018;11(5):547-559. doi: 10.1007/s40271-018-0312-x.

Teva Media

Inquiries TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor

Relations

Inquiries TevaIR@Tevapharm.com

Copyright 2026 GlobeNewswire, Inc.